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- Nothing in biology makes sense except in the light of evolution. - 
Theodisius Dobzhansky 
     Genetics and the Origin of Species  
      (1937, Columbia Univ. Press, New York) 
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Zusammenfassung 
Das Wilms-Tumorgen 1 (WT1) repräsentiert eine der erfolgversprechendsten 
Zielstrukturen für spezifische immuntherapeutische Ansätze bei myeloischen 
Leukämien sowie bei einer Reihe weiterer hämatologischer und solider Neoplasien. 
Mehrere Studien, darunter eine Studie aus unserer Klinik zur klinischen Wirksamkeit 
und Relevanz von WT1 in Kombination mit KLH (engl. keyhole limpet hemocyanin) 
und hGM-CSF (engl. Granulocyte-macrophage colony-stimulating factor), zeigen 
eine hohe Immunogenität von WT1-Peptiden durch Induktion spezifischer T-Zellen 
bei  50-70% eigentlich austherapierter Patienten und Hinweise für klinische Effizienz 
[1-3]. 
Die allerdings nur selten dauerhaft etablierbaren T-Zell-Frequenzen stellen eine der 
wichtigsten Hürden auf dem Weg zur allgemeinen klinischen Anwendung dar. 
Bislang fehlen jedoch systematische Untersuchungen, die analysieren, aus welchem 
Grund die Konstitution eines immunologischen Gedächtnisses in diesem Kontext so 
herausfordend ist. Diese Arbeit sollte deshalb einen Einblick über die T-Zell-
Funktionalität, die phänotypische Zusammensetzung der T-Zell-Population als auch 
über die lytische Effizienz WT1-spezifischer, zytotoxischer T-Zellen gegenüber 
leukämischen Blasten bieten (Abbildung 1).  
 
Abbildung 1: Übersicht über die in dieser Arbeit untersuchten Mechanismen, welche potentiell 
zu einer  Einschränkung einer effektiven anti-Tumor-Immunantwort führen können.  
 
Ergänzend zu den funktionellen Untersuchungen fehlen detaillierte Analysen über 
die Präsenz und Induktion verschiedener Blasten-Charakteristika, die indirekt die 
Sensitivität gegenüber der T-Zell-vermittelten Zytotoxizität vermindern, als auch 
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ausreichende Erkenntnisse über die direkte Suppression WT1-spezifischer T-Zellen 
durch die Leukämie. 
Aus diesem Grunde sollte untersucht werden, ob und wie stark die Sensitivität von 
WT1-spezifischen T-Zellen gegenüber leukämischen Blasten von den 
Expressionsniveaus anti-zytotoxischer/apoptotischer Proteine und der Präsenz 
weiterer immunsupprimierender Faktoren abhängt. Hierunter fällt, neben der 
Sekretion von löslichen als auch der Präsentation von membranständigen 
Immunmodulatoren durch die Blasten, vornehmlich die Präsenz neu-induzierter 
immunregulatorischer Zellen.  
Humorale Immunität gegenüber WT1 und KLH in AML-Patienten 
durch die Vakzinierung mit einem WT1-Epitop, KLH und GM-CSF 
Das grundlegende Prinzip jeder Impfung ist in der Regel die Etablierung eines 
immunologischen Gedächtnisses gegen das Zielpathogen [4]. Idealerweise führt eine 
Impfung deshalb zu einer Aktivierung des kompletten Repertoires des 
Immunsystems. Im Falle der Einzelpeptid-basierten Immuntherapie werden durch 
das Antigen  in den meisten Fällen nur die zytolytischen Effektorzellen, die ZTLs, 
aktiviert. Zur Unterstützung des Aktivierungsprozesses werden dem Vakzin deshalb 
Adjuvantien wie Monensin, KLH und hGM-CSF hinzugefügt, um eine Antigen-
unspezifische Helferantwort von Tumorzellen zu induzieren. Dies sollte zur 
Freisetzung von zusätzlichem „natürlichem“ antigenen Material führen, welches eine 
Reaktion des kompletten Immunsystems hervorrufen sollte. Untersuchungen, die die 
humorale Antwort der Patienten gegenüber dem WT1-Protein evaluierten, zeigten, 
dass im Zuge der Vakzinierung eine Induktion von WT1-spezifischen 
Immunglobulinen stattfindet. Diese Induktion beschränkt sich allerdings nur auf den 
Isotyp M (IgM), der von naïven B-Zellen produziert wird und als Marker für eine 
Initialantwort dienen kann. Der sogenannte isotype-switch (Isotypen-
Klassenwechsel), die Produktion des Isotyps G (IgG) an Stelle von IgM, welcher die 
Etablierung eines immunologischen B-Zell-Gedächtnisses repräsentiert, findet in 
unserem Patientenkollektiv im Laufe der Vakzinierung allerdings nicht statt. Dies 
kann vermutlich auf eine nicht ausreichende Stimulation von CD4-Helfer-Zellen 
durch das MHC-Klasse I-restringierte WT1-Peptid zurückgeführt werden, eine 
Annahme, die durch den nachweisbaren Isotypen-Klassenwechsel bei KLH-und 
hGM-CSF-spezifischen Immunglobulinen gestützt wird (Absatz 4.1). 
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Phänotypische und funktionale Analysen der zellulären Immunität 
in AML-Patienten vakziniert mit einem WT1-Epitop, KLH und 
GM-CSF 
Weitere Untersuchungen sollten Aussagen zur T-zellulären Funktionalität als auch 
zur Zusammensetzung der T-Zell-Population im Vakzinierungsverlauf zulassen. Die 
Bestimmung erfolgte zu zwei Zeitpunkten, dem Vakzinierungsstartpunkt und 
während des Vakzinierungsverlaufs in Woche 10.  
Die Ergebnisse dieser Experimentenreihe zeigten zwar ein heterogenes Bild, was die 
Zytokinfreisetzung und/oder Zytolysekapazität betrifft, wiesen aber keine 
signifikante Korrelation zum klinischen Ergebnis auf. Allerdings konnte bei diesen 
Messungen nachgewiesen werden, dass eine bereits bestehende oder während der 
Therapie akquirierte T-Zell-Anergie den klinischenVerlauf stark beeinflusst.  
Der wiederholte Kontakt einer T-Zelle mit ihrem Antigen führt zur gesteigerten 
Expression von Faktoren, die die Aktivierungsschwelle der T-Zelle bei einem neuen 
Kontakt erhöhen [5, 6]. Dies führt letztendlich zu einem anergischen Status der Zelle, 
welcher durch eine geringe bis gar nicht vorhandene Reaktivität der T-Zelle 
gekennzeichnet ist. Dieser Prozess dient eigentlich dazu, nach der Pathogen-
Eradikation die Immunantwort langsam wieder einzudämmen [7], ist im Kontext der 
Immune-Surveillance allerdings kontraproduktiv. 
In dieser Arbeit konnte gezeigt werden, dass sich die Expression des Immun-
Regulators PD-1 (programmed death-1 receptor) negativ auf die mittlere 
Überlebensdauer der betroffenen Patienten auswirkt (p=0,05). Ein ähnliches Bild 
zeigte sich für diesen Faktor auch in Bezug auf die biologische Aktivität des 
Vakzins, welche über die Abnahme von WT1-RNA-Transkripten zu denselben 
Zeitpunkten bestimmt wurde. Patienten mit geringem PD-1-Niveau zeigen eine 
deutlich bessere Bewältigung der Tumorlast, erkennbar durch eine Reduktion der 
WT1-Transkripte im Verlauf der Therapie (p=0,057), als Patienten mit höheren PD-
1-Werten zu Beginn der Vakzinierung.  
Weiterhin zeigen die phänotypischen Untersuchungen auch bei der T-Zell-
Population Einschränkungen bei der Entwicklung eines effektiven immunologischen 
Gedächtnisses. Nach dem ersten Kontakt einer naiven T-Zelle mit ihrem spezifischen 
Antigen reift die Zelle und exprimiert Oberflächenmoleküle, die ihr das Einwandern 
in sekundäre Lymphorgane erleichtern, um dort als Gedächntisszelle zu verbleiben [8, 
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9]. Eines dieser Oberflächenmoleküle, CCR7 (cc-chemokine receptor 7), spielt in 
unserem Impfschema eine wichtige Rolle. Das Patientenkollektiv zeigt im Verlauf 
zwei wesentliche Verhaltensweisen, welche die CCR7-Expression betreffen: bei 
ungefähr der Hälfte der Patienten nimmt die Frequenz an CCR7+-T-Zellen deutlich 
ab, während sich bei den restlichen Patienten die entsprechenden Frequenzen 
erhöhen. Die Abnahme von CCR7+-T-Zellen kann, ebenso wie die Präsenz von PD-
1, mit einem negativen klinischen Verlauf korreliert werden (p=*) (Absatz 4.2).  
Einfluss von immunregulatorischen Zellen auf die Therapieeffizienz 
Ein weiterer wichtiger Punkt bei der Analyse von Immunresistenzmechanismen 
betrifft die Präsenz immunsupprimierender Zellen. Auch diese dienen eigentlich zur 
Hemmung einer Immunantwort nach der Eradikation eines Pathogens, können aber 
in der Tumortherapie einen negativen Einfluss ausüben [10-12]. Die ermittelten Daten 
zeigten zu beiden Zeitpunkten erhöhte Frequenzen von regulatorischen T-Zellen als 
auch von Suppressorzellen myeloiden Ursprungs, sogenannten myeloid-derived 
suppressor cells (MDSCs), ein Effekt, der für die AML-Erkrankung allerdings 
bekannt ist. Jedoch lieferte der Vergleich zwischen den beiden Zeitpunkten für keine 
der beiden Zellpopulationen einen signifikanten therapeutischen Zusammenhang mit 
reduzierter T-Zellfunktionalität oder dem klinischen Verlauf (Absatz 4.3.2.1).  
Immunevasion durch Leukämische Blasten und die resultierende 
Interferenz mit der Therapie 
Im Kontext von Immunresistenzmechanismen sollte auch immer ein Fokus auf der 
Immunevasion des Pathogens liegen: wenn man Immunität unter einem 
evolutionären Gesichtspunkt betrachtet, übt das immunologische 
Verteidigungssystem des Wirtes einen großen Selektionsdruck auf entartete Zellen 
oder andere Pathogene aus. In diesem Zusammenhang treten oft einzelne 
Tumorzellen auf, die durch aktive oder passive Mechanismen in der Lage sind, der 
spezifischen Immunabwehr zu entgehen und im späteren Verlauf ein Rezidiv oder 
Metastasen zu verursachen. Interessanterweise ahmen diese aktiven Mechanismen 
oft konventionelle immunologische Prozesse nach, die üblicherweise eine 
Immunantwort dämpfen. Leukämien treten hier verstärkt in den Vordergrund, da sie, 
ebenso wie alle Immunzellen, hämatopoietischen Ursprungs sind und deshalb 
Zusammenfassung 
 7 
potentiell über ein ähnliches Transkriptom wie diese verfügen [13, 14]. Aus diesem 
Grund treten bei Leukämien häufig Membran-gebundene oder lösliche 
Immunsuppressiva wie TGF-, PD-L1, IL-10, IDO, HMOX, CXCR4, VEGF, PI-9 
und IL-8 auf, welche die Sensitivität der Blasten gegenüber T-Zell-vermittelter 
Apoptose reduzieren und/oder als negative Regulatoren auf zytotoxische T-Zellen 
wirken.  
 
Vergleichende Untersuchungen an Knochenmark- oder Blutproben von Patienten, 
bei denen im Verlauf der Therapie ein Rezidiv auftrat, zeigten, dass die Expression 
der oben genannten Immunmodulatoren zum Initiierungs- und/oder Rezidivzeitpunkt 
innerhalb der Patienten heterogen verteilt waren und somit keinen generellen Marker 
auf ein im Therapieverlauf auftretendes Rezidiv beinhalten. Nichtsdestotrotz können 
die individuelle Präsenz und Induktion dieser Marker einen Einfluss auf den 
klinischen Verlauf bei einzelnen Patienten ausüben.  
In Übereinstimmung mit den Ergebnissen über die PD-1-Präsenz auf T-Zellen zeigte 
auch die veränderte Expression des PD-1-Liganden (PD-L1) auf Blasten eine 
Korrelation zur mittleren Überlebensdauer (p= *; Figure 32 A): ein Teil der Patienten 
mit zu Beginn der Therapie stark erhöhtem Level an PD-L1 mRNA, zeigte im 
Verlauf der Therapie eine starke Abnahme dieser Werte. Interessanterweise traf dies 
nur auf Patienten zu, die am meisten von der Therapie profitierten und am längsten 
rezidivfrei blieben. Erklärungen hierzu sind rein spekulativ, allerdings zeigen 
aktuelle Studien, dass PD-L1-Level vom Reifungsstatus der Zelle als auch durch 
Umgebungsfaktoren wie IFN-y beeinflusst werden können [15, 16]. Zukünftige 
Untersuchungen sollten Fragestellungen hierzu beinhalten.  
Ein weiterer interessanter Aspekt dieser Untersuchungen wird durch die gegenläufige 
Regulation von TGF-β repräsentiert. Während TGF-β-mRNA-Level in Patienten mit 
frühem Rezidiv sinken, erhöhen sich die TGF-β-mRNA-Level in Patienten mit 
spätem Rezidiv (Figure 32 B). Dies scheint paradox, da im Kontext eines Rezidivs 
TGF-β eher eine Rolle als Tumorpromotor zugedacht wird, allerdings zeigen 
Studien, dass eine Störung in der frühen Phase des TGF-β-Signalweges zu einer 
erhöhten Proliferations- und somit auch Mutationsrate von Tumorzellen führen 
kann [17]. Prozesse, die erst zu einem späteren Zeitpunkt mit der TGF-β 
Signalkaskade interferieren, führen im Gegensatz dazu, dass sich die Expansion 
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eines Tumors langsamer, dafür aber wesentlich invasiver vollzieht. Auch hierauf 
sollte in weiterführenden Studien ein Augenmerk gerichtet werden.  
Resumée und Ausblick 
Die ermittelten Daten zeigen, dass in unserem spezifischen Therapieansatz, der 
wiederholten Vakzinierung von AML-Patienten mit einem HLA-A201-restringierten 
WT1126–134 -Epitop in Kombination mit GM-CSF und KLH, eine eingeschränkte T-
Zell-Funktionalität einen wesentlichen Grund für die beobachtete verminderte 
Therapieeffizienz darstellt. Immunresistenzmechanismen leukämischer Blasten 
spielen hierbei keine übergeordnete Rolle, individuelle Effekte können aber nicht 
ausgeschlossen werden. Ebenso scheint es, dass auch die Präsenz von 
immunregulatorischen Zellen wie Tregs oder MDSCs nicht durch die Vakzinierung 
manipuliert wird und dass diese keinen generellen Einfluss auf die Therapieeffizienz 
ausüben.  
 
Diese Arbeit, wie auch die Arbeiten anderer zeigen, dass die Krebsimmuntherapie 
und besonders die Tumorvakzinierung ein wichtiges, attraktives und wachsendes 
Forschungsfeld mit hohem Potential repräsentiert, welches allerdings, aufgrund der 
großen Bandbreite an Therapieformen und Tumorentitäten, durch eine hohe 
Komplexität gekennzeichnet ist. Der Abschluss einer wichtigen Priorisierungsstudie 
für Tumorantigene als auch der aktuelle Dialog über die Harmonisierung von 
Vakzinestudien sollten in Zukunft zu einer gesteigerten Transparenz als auch zu 
einem optimierten Transfer von Erkenntnissen führen, um die Tumortherapie 
effektiver und für den Patienten angenehmer zu gestalten. 
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Abbreviations 
 
AA  amino acid 
Ab  antibody 
ALL  acute lymphoblastic leukemia 
AML  acute myeloid leukemia 
APC  allophycocyanin 
APCs  antigen presenting cells 
BFA  Brefeldin A 
B-NHL  B cell Non-Hodgkin Lymphoma 
BSA  bovine serum albumine 
CD  cluster of differentiation 
cDNA  complementary DNA 
CR  complete remission 
CTL  cytotoxic T cell 
DC  dendritic cell 
DMEM Dulbecco’s modified Eagles medium 
DMSO  dimethylsulfoxid 
DNA  deoxyribonucleic acid  
dNTP  deoxyribonucleotide-triphosphate 
EDTA  ethylendiamid-tetra-acedic acid 
ELISA  enzyme-linked immunosorbent assay 
EORTC  European Organization for Research 
and Treatment of Cancer 
et. al.  et alii (latin: „and associates“) 
FACS  fluorescence activated cell sorting 
FDA  U.S. Food and Drug Administration 
FITC  fluorescein-isothyocyanate 
FSC  forward-scatter 
GAM  goat-anti-mouse 
GM-CSF  granulocyte-macrophage colony-
stimulating factor 
HCV  hepatitis C virus 
HIV  human immunodeficiency virus 
HLA  human leukocyte antigen 
Ig  immunoglobulin 
IL  interleukin 
IMCs  immature myeloid cells 
IU  international units 
KLH  keyhole limpet hemocyanin 
LB  lysogeny broth 
MACS  magnetic-activated cell sorting 
MDSC  myeloid-derived suppressor cells 
MHC  major-histocompatibility-complex 
mRNA  messenger RNA 
NADH+  nicotinamide adenine dinucleotide 
NCI  National Cancer Institute 
NIH  National Institutes of Health 
NK cell  natural killer cell 
PBMC  peripheral blood mononuclear cells 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PD  progressive disease 
PE  R-phycoerythrin 
PerCP  peridinin chlorophyll protein complex 
PFS  progression-free survival 
PR  partial remission 
RCC  renal cell carcinoma 
RNA  ribonucleic acid 
RPMI  Roswell Park Memorial Institute 
medium 
qRT-PCR  quantitative reverse-transcriptase 
polymerase chain reaction 
SAV  streptavidin 
SD  stable disease 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide 
gel electrophoresis 
SSC  side scatter 
SEB   staphylococcus aureus enterotoxinB 
SLOs  secondary lymphoid organs 
TAA  tumor-associated antigen 
TCM  central memory T cell 
TCR  T cell receptor 
TEFF  effector T cell 
TEM  effector memory T cell 
TGF  transforming growth factor 
TH1  CD4+ T-helper cell, producing type-1 
cytokines 
TH2  CD4+ T-helper cell, producing type-2 
cytokines 
TH17  CD4+ T-helper cell, producing IL-17 
TIL  tumor infiltrating lymphocytes 
TNF  tumor necrosis factor 
Treg  regulatory T cell 
WHO  World Health Organization 
WT1  Wilms’ tumor gene 1 
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1 Introduction 
With the discovery of antibiotics and improving medical knowledge in diagnosis and 
treatment of once fatal diseases, demographic aging results in cancer being the 
second most common cause of death after heart disease in high-income countries in 
2004 [18]. Despite encouraging advances in early diagnosis and improvements in 
therapy and combination therapies, cancer remains a major public health dilemma, as 
substantial groups of cancer patients lack effective treatment options, and even larger 
groups lack curative therapies [19]. 
Over the past two decades, advances in basic immunology as well as improved 
understanding of the interactions between the immune system and tumors, generated 
a renewed interest on Ehrlich’s postulate to approach cancer treatment 
immunologically [20-23]. The concept of cancer immunotherapy provides an 
alternative perspective, since it is not associated with many of the drawbacks of 
conventional therapies such as chemotherapy, radiotherapy and surgery, which are 
rather unspecific, accompanied by more or less severe adverse effects and do, in a lot 
of cases, not lead to a permanent cure. Those treatments are highly active in 
eliminating the major tumor mass, but are less effective in eliminating residual 
cancer cells and in preventing relapse of the disease. These occasionally detrimental 
insufficiencies shift current cancer research to a more biological approach on tumor 
therapy: 
 
In the early 20th century, Paul Ehrlich was the first to suggest, that the immune 
system plays a pivotal role in the protection against tumors [24]. Since then, the 
biological therapy of cancer has evolved in an impressive manner: From 1957 on, 
Burnet and Thomas theorized that any organism sufficiently complex and with a life 
span long enough to be threatened by cancer must evolutionary acquire mechanisms 
capable of protecting against tumors. These considerations led to the 
immunosurveillance hypothesis [25, 26], describing the guarding nature of lymphocytes 
by constantly eliminating transformed cells in immunologically intact individuals - a 
milestone in cancer immunotherapy. However, as many cancers are known to appear 
in the setting of immune/inflammatory responses [27], the concept of 
immunostimulation, dating back to Rudolf Virchow’s work in the 19th century [28], 
competed with immunosurveillance on describing the cause of tumor promotion. 
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The proof and acceptance of Virchow’s thesis on immunostimulation and it’s co-
existance with immunosurveillance finally led to the understanding of immune 
editing [20, 29], a process describing the adaption and evolution of tumor cells in 
regards to the selectional pressure mediated by the immune system, thereby sculpting 
the immunogenic phenotype of tumors as they develop. This effect reveals the 
complex nature of tumor immunotherapy. Briefly, cancer immunoediting comprises 
three processes, usually refered to as “the three Es”: 
a) eliminiation/immunosurveillance,  
b) equilibrium, a phase in which the immune system iteratively promotes the 
generation of immune-resistant tumor variants, and 
c) escape, a phase in which the immune-sculpted variants expand in an 
uncontrolled manner. 
 
Based on this model, tumors can be specifically targeted and eliminated by the 
immune system (elimination), but if the immune system is not able to completely 
eradicate the nascent tumor, the tumor might persist but is controlled by the immune 
system (equilibrium). At some point at this stage, single tumor cells may transform 
and elude immune control (escape), thereby causing relapses [20].  
However, Blankenstein et al. advance the view, that spontaneous tumors are indeed 
immunogenic, but that the resulting immune responses are unable to efficiently limit 
tumor growth [30]. Which of both features actually reflects the mechanisms involved 
in the immunesculpting of the tumor remains under strong discussion and 
investigation.  
With the prosperous 90s, numerous achievements could be implemented in the 
clinical therapy of cancer: The FDA (U.S. Food and Drug Administration) approval 
of IL-2, GM-CSF (granulocyte-macrophage colony-stimulating factor) and the anti-
CD20 antibody Rituximab altered the field of immunotherapy significantly [31-33]. The 
climax of this development was reached by Pierre van der Bruggen and colleagues 
who reported the first identification of a tumor-specific antigen recognized by 
cytolytic T cells in humans, reinforcing the idea that tumor antigens can elicit a 
detectable tumor-specific immune response [23]. Furthermore, with the observation, 
that cytotoxic lymphocytes infiltrate tumor tissue [34], are able to lyse tumor cells in 
vitro [35] and are associated with better prognosis [36] tumor therapists started to 
understand and actively modulate the capacity of T cell directed therapy.  
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Nevertheless, with the broad diversity of tumors, and them being able to potentially 
escape many, if not all, immunological offensives in just as diverse ways, there are 
still a lot of questions to be answered and obstacles to overcome while optimizing 
cancer treatment. In this context, the present work is thought to enlighten the 
understanding of immune resistance mechanisms in the setting of peptide-based 
vaccination therapy in acute myeloid leukemia. 
1.1 Acute myeloid leukemia 
Acute myeloid leukemiaa (AML) is a relatively rare disease, accounting for a german 
incidence rate in adults of approximately 4.3 cases per 100 000 in men and 2.9 cases 
per 100 000 in women, respectively [37, 38]. It is the most common acute leukemia 
affecting adults, and its incidence increases with age - an important fact regarding 
aging populations. AML results in a massive outgrowth of leukemic blasts (Figure 1) 
in the bone marrow leading to a suppression of normal hematopoiesis. This usually 
results in a drop of red blood cells, platelets, and normal white blood cells in the 
peripheral blood, which could either be associated with leukocytosis, as result of 
leukemic blasts migrating into the peripheral blood or leucopenia, when leukemic 
blasts remain in the bone marrow.  
 
Figure 1: phylogenetic tree of the hematopoietic lineage. AML can affect any cell type derived 
from a common myeloid progenitor. Adapted and modified from Janeway’s Immunobiology [39] 
 
                                                 
a Greek: λευκός (leukós) „white“ und αἷμα (haima) „blood“ 
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Although no specific cause of the disease could be identified yet, several risk factors 
for AML are known. The National Cancer Institute (NCI) lists those on its 
homepageb:   
 Being male.  
 Smoking, especially after age 60. 
 Having had treatment with chemotherapy or radiation therapy in the past. 
 Having had treatment for childhood acute lymphoblastic leukemia (ALL) in 
the past. 
 Being exposed to atomic bomb radiation or the chemical benzene. 
 Having a history of a blood disorder such as myelodysplastic syndrome. 
The disease pattern may include symptoms as fatigue, shortness of breath, easy 
bruising and bleeding, and increased risk of infection. AML usually progresses 
rapidly and is typically fatal within weeks or months if left untreated due to massive 
infections or bleedings. AML can be classified according to the WHO [40, 41] - or the 
French-American-British (FAB) [42] - classification system (comparative summaries 
in Table 1 and Table 2).  
French-American-British (FAB) Classification 
M0 Minimally differentiated leukemia 
M1 Myeloblastic leukemia without maturation 
M2 Myeloblastic leukemia with maturation (t(8;21)(q22;q22), t(6;9)) 
M3 Hypergranular promyelocytic leukemia (t(15;17)) 
M4 Myelomonocytic leukemia (inv(16)(p13q22), del(16q)) 
M4 Eo Increase in abnormal marrow eosinophils (inv(16), t(16;16)) 
M5 Monocytic leukemia (del (11q), t(9;11), t(11;19)) 
M6 Erythroleukemia  
M7 Megakaryoblastic leukemia (t(1;22)) 
Table 1: Acute Myeloid Leukemia Classification Systems according to the FAB. T= translocation, 
inv = inversion, del = deletion, p/q = structural nomenclature of the chromosome: p= short arm, q= 
long arm. 
While the FAB divides AML into 8 subtypes M0 through to M7, based on 
morphological as well as on immunological criteria, the WHO-classification attempts 
to define biological entities, reflecting the fact that an increasing number of acute 
leukemias can be categorized based upon their underlying cytogenetic or molecular 
genetic abnormalities that form clinico-pathologic-genetic entities [41, 43].  
                                                 
b www.cancer.gov 
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World Health Organization Classification 
AML with recurrent genetic 
abnormalities 
AML with t(8;21)(q22;q22);RUNX1/RUNX1T* 
AML with abnormal bone marrow eosinophils (inv(16)(p13q22) or 
t(16;16)(p13;q22);CBFβ/MYH11)* 
Acute promyelocytic leukemia (AML with t(15;17)(q22;q12) (PML/RARα) 
and variants)* 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
AML with multilineage 
dysplasia 
Following a myelodysplastic syndrome or myelodysplastic syndrome/ 
myeloproliferative disorder 
Without antecedent myelodysplastic syndrome 
AML and myelodys-plastic 
syndromes, therapy-related 
Alkylating agent-related 
Topoisomerase type II inhibitor-related 
Other types 
AML not otherwise 
categorized 
AML minimally differentiated 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic and monocytic leukemia 
Acute erythroid leukemia 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma Syn.: extramedullary myeloid tumor; granulocytic arcoma;chloroma 
Myeloid proliferations related 
to Down syndrome 
Transient abnormal myelopoiesis (syn.: transient myeloproliferative disorder) 
Myeloid leukemia associated with Down syndrome 
Blastic plasmacytoid dendritic 
cell neoplasm 
 
Acute leukemias of ambiguous 
lineage 
Acute undifferentiated leukemia 
Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1_ 
Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged 
Mixed phenotype acute leukemia, B/myeloid, NOS 
Mixed phenotype acute leukemia, T/myeloid, NOS 
Provisional entity: Natural killer (NK)–cell lymphoblastic leukemia/lymphoma 
Table 2: Acute Myeloid Leukemia Classification Systems according to the WHO. * Diagnosis is 
AML regardless of blast count; T= translocation, inv = inversion, del = deletion, p/q = structural 
nomenclature of the chromosome: p= short arm, q= long arm. 
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On this account, AMLs with cytogenic abberations are separated from therapy-
induced or morphological AMLs. Consequently, the different subtypes exhibit 
varying prognoses and responses to therapy. Conventional treatment options for 
AML are limited and consist primarily of chemotherapy and/or stem cell 
transplantation. With standard chemotherapy, the majority of AML patients reach a 
complete remission, but only 20% to 40% achieve a disease-free survival of more 
than 5 years [44]. Chemotherapeutic treatment is generally composed of two phases: 
induction and postremission/consolidation therapy. The goal of the induction phase is 
to reach a complete remission, meaning that no disease can be detected with 
available diagnostic methods. This already implies that even after complete 
remission, small numbers of leukemic cells can still remain in the body and if no 
further postremission or consolidation therapy is given, almost all patients will 
eventually relapse. The goal of consolidation therapy therefore is to eliminate any 
residual undetectable disease and to achieve a permanent cure. Because of its 
severity, hematopoetic stem cell transplantation (HSCT) usually is only performed in 
high risk patients and if previous chemotherapy failed, but inclusion criteria are well 
defined and not all patients are candidates for stem cell transplantation.  
For those patients the only curative alternative, besides palliative care, is the 
inclusion in a clinical trial. Current investigations include cytotoxic drugs, targeted 
therapies, adoptive T cell transfer and antigen-directed immunotherapy. The better 
characterization of graft-versus-leukemia effects after allogeneic stem cell 
transplantation, donor lymphocyte infusions, and identification of leukemia-
associated antigens have set the headstone of immunotherapy strategies. 
1.2 Tumor antigens 
The term tumor antigen describes antigens, which are exclusively or predominantly 
expressed on tumors and therefore are principally adequate to induce a tumor-
specific immune response. This feature appoints tumor antigens their role as major 
targets in cancer immunotherapy, as well as important diagnostic markers [45]. Like 
all other antigens, tumor antigens are presented via MHC-class I- or MHC-class II 
and therefore represent target structures for cytotoxic T-lymphocytes (CTLs), T-
helper cells as well as B-cells [46-48].  
As noted before, tumor antigens are not necessarily tumor specific: they usually are 
over-expressed as a result of the malignant transformation of a tumor cell, leading to 
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an unnatural high “concentration” of an habitually factor which has made the use of 
the term tumor-associated antigens (TAAs) more appropriate [49]. In general, tumor-
associated antigens can be divided into five groups: (1) Tumor-specific shared 
antigens (formerly: Oncospermatogonal (Cancer/Testis)-antigens) that are expressed 
in a range of different tumor types but not in normal tissues except testis, (2) 
differentiation antigens, (3) antigens encoded by mutated normal genes, (4) self-
antigens, over-expressed in malignant tissues and (5) antigens derived from 
oncogenic viruses [50, 51]. A short register of the most prominent TAAs is shown in 
Table 3. 
Group Antigen 
(1) Tumor-specific shared antigens MAGE[52], RAGE[53], NY-ESO-1[54] 
(2) Differentiation antigens 
MART-1/Melan-A[55], Tyrosinase[56], 
gp100[57]. PSA[58], AFP[59] 
(3) Antigenetic epitopes of mutated genes CDK4[60], Caspase-8[61], p53[62] 
(4) Self-antigens derived from malignant tissues HER-2/neu[63, 64], WT1[65] 
(5) Viral antigens HPV[66], EBV[67] 
Table 3: Summary of the major tumor antigen-groups and some exemplary antigens. 
Subgrouping according to Van den Eynde and van der Bruggen [51]. 
 
The serological identification of antigens by recombinant expression cloning 
(SEREX) [68] as well as the process of digital prediction by online databases (e.g. 
SYFPEITHIc or BIMASd) [69, 70] has led to the identification and characterization of 
numerous TAAs thereby also mounting the number of identified tumor antigens for 
hematopoietic tumors. Interestingly, in the case of myeloid tumors like chronic 
myeloid leukemia (CML), AML or myelodysplastic syndrome (MDS), it seems that 
most of the TAAs associated with these diseases can be related to important 
functions affecting the cell-cycle and/or cell-proliferation. [71]. The high functional 
relevance of these TAA reduces the risk of induction of TAA-loss as tumor-escape 
variants. 
1.3 Targeted immunotherapy and WT1 
In contrast to all other standard modalities (surgery, chemotherapy, radiotherapy, and 
adaptive immunotherapy), an effective vaccine-induced immune response against 
                                                 
c http://www.syfpeithi.de/ 
d http://www-bimas.cit.nih.gov/molbio/hla_bind/ 
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tumor uniquely may bear the potential to last a lifetime [72]. The rationale of 
therapeutic cancer vaccines is to “teach” the patient's immune system to specifically 
recognize and eliminate tumor cells. When fully activated the immune system has 
immense potential, as is apparent from several autoimmune diseases (e.g. lupus 
erythematosus[73], psoriasis[74] and pemphigus vulgaris[75]), mismatched transplanted 
organs undergoing rapid immunological attack and rejection, as well as, in 
opposition to the later, graft-versus-host disease (GvHD) [76]. These examples 
demonstrate, that one of the most important features of an intact immune system is to 
differentiate between “self” and “non self”. In the case of external pathogens like 
bacteria, viruses or transplants this system usually works efficiently, but due to the 
fact that tumors normally represent derivatives from mutated “self”-cells, the 
immune-system may be constricted in its activity. 
The tight discrimination between tumors and normal tissue by the immune system is 
therefore crucial for the eradication of the tumor and the survival of the affected 
individuals. To support the immune system in this task, the recognition of tumor cells 
can be primed and facilitated by adaptive and/or active immunotherapy. In contrast 
to adaptive immunotherapy, in which ex vivo-generated target specific cells or 
antibodies are reinfused or administered, active immunotherapy is characterized by 
the application of vaccines that aim at eliciting a specific immune response against 
over-represented tumor antigens in vivo. [72].  
1.3.1 Tumor vaccination 
Vaccinatione represents a very potent and successful strategy to treat or prevent 
diseases. Intentionally used to describe the injection of smallpox vaccine, the term 
today refers to a general administration of antigenic agents to stimulate adaptive 
immunity to recognize a specific antigen and to establish an immunological 
memory [4].  
Indifferent of the vaccine-approach, the common feature of all represents the 
delivery of an antigenic structure that can be uptaken and be presented by antigen-
presenting cells (APCs) via MHC molecules. The recognition of these peptide/MHC-
complexes by T cells potentially leads to the stimulation of the antigen-specific 
lymphocytes as well induces further co-stimulatory signals for a proper activation of 
                                                 
e from the latin word vacca – cow. The term was first used by Edward Jenner, a  reference  to 
the immunization for smallpox by inoculation of humans with cow-pox virus. 
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the adaptive immune system. Ideally, this cascade results in the generation of 
immediate effector T cells, as well as in a permanent reservoir of memory T cells 
which provide long-term protection upon second encounter with the same pathogenic 
structure. In cancer immunotherapy, this is accomplished by the usage of defined 
TAAs or tumor lysate applied as mainly cell-based vaccines, DNA- or RNA-based 
vaccines, vector-based vaccines and protein- or peptide-based vaccines. To achieve a 
better stimulation the antigen is usually combined with adjuvant immune stimulators 
or reponse modulators. Independent of the technique, all strategies aim at the 
induction of an endogenous, long-lasting tumor response similar to those in antiviral 
or antimicrobial vaccine-settings.   
Cancer vaccination can either be therapeutic or prophylactic, treating existing cancer 
or preventing either infections with cancer-causing viruses or the development of 
cancer in certain high risk individuals, respectively. 
Various strategies for therapeutic cancer vaccines have been proposed to elicit 
immune responses against tumor antigens, including cell-based vaccines, DNA- or 
RNA-based vaccines, vector-based vaccines, and protein- or peptide-based vaccines 
(Figure 2) [77, 78].  
 
Figure 2: General vaccine modalities. Three main vaccination types are totally available against 
cancer such as cellular-based vaccines, protein-based vaccines and vector-based vaccines. Each these 
types divide into the subgroups in detail. Among them, DNA vaccines and protein/peptide vaccines 
have been further involved in vaccine design. Adapted and modified from Bolhassani et al. [78] 
 
In the past years the efforts to establish preventive vaccines targeting tumor-inducing 
viruses have been successful and vaccines against human papilloma virus (HPV) [79] 
and hepatitis B virus (HBV) [80] associated cancers, are well established. 
In contrast to well-established microbial or virally induced diseases, a real proof of 
efficacy for anti-tumor vaccines has only be demonstrated for a very few disease 
settings. In contrast to external pathogens, the major hurdle in developing efficient 
Introduction 
 22 
cancer vaccines is represented by the lack of appropriate and distinct tumor-specific 
antigens and the weak immunogenicity displayed by tumor-associated antigens, as 
inherited by all self-antigens. Additionally, the immunotherapeutic targeting of a 
shared antigen aims at breaking otherwise exhibited tolerance and to induce 
autoimmunity, measurements that increase the curative complexity.  
Besides the natural obstacles, the huge variety of antigens, the different systems used 
to deliver the vaccine, as well as the use of different adjuvants to costimulate specific 
compartments of the immune system, limit the ability to discriminate and to compare 
the different clinical trials.  
In the context of already manifested tumors, the failing induction of effective and 
long-lasting tumor-specific immune responses remains the most intriguing point. Up 
to date, only one vaccine with proven benefit in hormone-refractory prostate cancer 
is FDA-approved and commercially available [81].  
Therefore, the current formation of initiatives to facilitate and to structure cancer-
vaccine research possibly provides a catalytic boost to the implementation of 
immune therapeutic cancer-vaccines in the clinic in a near future [82]. 
1.3.2 Protein- and Peptide-based vaccination 
As briefly mentioned in section 1.3.1, vaccination with peptides, besides cell-based 
or nucleic acid-based vaccines, represents a very interesting and prospering approach 
of active tumor therapy. Peptides play critical roles in determining the magnitude and 
specificity of cell-mediated and humoral immunity, and can contain the minimal 
sequences necessary for immunomodulation. Furthermore, peptides can be easily 
synthesized and characterized, and are generally more stable than whole pathogens 
or full-length proteins [83]. 
The settings cover a broad spectrum of regimens, including single agents or 
combinations of proteins, heat-shock proteins (HSPs), peptides and agonistic 
peptides, anti-idiotype vaccines and fusion proteins [72, 84-87]. In contrast to cell-based 
vaccines, production and storage of peptides are feasible and administration needs no 
time-consuming preliminary preparations. Additionally, as tumor cell lysates contain 
different self-proteins with no therapeutic benefit that are all potentially capable of 
generating an autoimmune response, the particular administration of specific TAAs 
prevents unwanted side-effects [72]. The clinical response towards peptide based trials 
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is generally determined by the induction of TAA-specific cytotoxic T-lymphocytes 
and/or the production of cytokines in the CD4+- and CD8+-T cell compartments.  
Under ideal conditions, vaccination leads to the activation of both, effector and 
memory T cells. The administered peptides usually are MHC-class-I restricted, 
stimulate CD8+ effector T cells and fail to deliver additional activation signals to T-
helper cells for appropriate CTL-costimulation. In the last few years a few MHC-
class-II-binding epitopes could be identified, but as they lack for the specific 
indication, the co-administration of immunogenic adjuvants, that induce an antigen-
unspecific T-helper response, is very common. The consecutive lysis of tumor cells 
is thought to release additional antigenic material, delivering additional triggers to 
a tumor-related immune response which can be assessed by the humoral response 
of the patients’ immune system [88-91]. 
In the same context, the use of immunogenic adjuvants produces an interesting side 
effect, as several groups have described an induction of specific immunoglobulins 
not only for the TAA-peptide, but also for the adjuvants used in different therapeutic 
settings [92]. This immunogenic effect permits a direct comparison between the 
developments of specific immune responses towards different kinds of antigens in 
the same setting. 
However, the use of specific proteins or peptides as targets for immunotherapy 
clearly requires a careful choice of the targeted TAAs and their epitopes, as peptide 
based vaccination also needs to overcome some methodical obstacles: As the nature 
of TAAs classifies them as self-proteins, they may exhibit a generally weak 
immunogenicity especially when using a single epitope [72]. Further, tumors can 
easily escape immune recognition through antigen mutation or loss. In addition, the 
use of peptides is usually HLA-restricted (e.g. epitope-based vaccines) and therefore 
limited to a specific subset of patients [2, 93]. Therefore, the ideal TAA should be 
widely expressed in different tumor types and also play a pivotal role in the 
oncogenic processes or in cancer cell survival, to avoid immune escape by mutations 
or loss of antigens by tumor cells [72, 82].  
1.3.3 Vaccine adjuvants 
As noted before tumor vaccination has been clinically tested and has been constantly 
improved over the past two decades. In general, current cancer vaccines are 
composed out of three parts: the antigene(s), adjuvant(s) and a delivery/application 
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system. This composition is consistent with the actual development of common 
vaccines, shifting from live attenuated or inactivated pathogens towards well-defined 
and purified antigenic substructures, which possess a bettter safety profile and can be 
produced in bulk quantities [94]. Nevertheless, this recent development requires the 
co-administration of immunmodulative adjuvants as these artificial antigenic 
substructures lack additional pathogenic compounds that enhance immunity by 
efficiently activating several components of the innate immune system when using 
live attenuated or inactivated pathogens [95, 96].  
The administration of adjuvants is a heterogenous field, including vaccine designs 
using single agents or combinations of different adjuvants depending on the effect 
the have to elicit. In the context of MHC-class-I restricted peptide settings, 
adjuvants are necessary to stimulate, activate and to recruit T-helper cells (TH). 
On this account, traditional methods use larger carrier proteins, such as keyhole 
limpet hemocyanin (KLH)[97]; a metalloprotein isolated from the mollusk 
megathura crenulata, or diphteria toxoid [98] that both provide sources of TH-cell 
epitopes. In current MHC-class-I restricted peptide vaccinations in AML, actual 
adjuvants besides TAA-specific MHC-class II epitopes, comprise CpG 7990 [99], 
a TLR9 agonist oligodeoxynucleotide, Montanide [2, 65], a water in oil emulsion, 
or GM-CSF [93, 100, 101]. In our setting, the MHC-class-I restricted peptide was 
administered in a combination of KLH and GM-CSF [93] (more detailed 
description in section 1.3.4). 
Concerning the delivery of antigenic peptides and adjuvants many designs and 
systems have been explored [78]. Generally, besides soluble antigens, delivery 
systems can be allocated to one of two substes, live vectors or non-living delivery 
systems. The latter ones, such as alum, liposomes, emulsions, immune stimulating 
complexes (ISCOMs) or biodegradable microparticels attempt to mimic the 
particulate nature of pathogens, by incorporating the antigen into particles which are 
retained in the body longer than soluble antigens and are more easily taken up by 
APCs. In contrast, live vectors, such as vaccinia virus, adenovirus and BCG (Bacillus 
Calmette-Guérin) represent antigenic structures in its native conformation from a 
relevant pathogen and thereby provide a co-stimulatoy immune-boosting effect [78, 
102]. The appropriate choice therefore depends on therapy goals, immunologic 
circumstances as well as suitability in the therapeutic context. 
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1.3.4 WT1 as therapeutic target 
The embryonic transcription factor WT1 has attracted considerable interest as target 
antigen for T cell based immune therapies[103] and was recently listed on position one 
in the ranking of the cancer antigen pilot priorization of the National Cancer 
Institute[82], attempting to compare current TAAs according to predefined and 
preweighted criteria of an “ideal” tumor antigen. 
WT1 was first described in 1990 as a tumor suppressor gene associated with Wilms 
tumor (a nephroblastoma)[104], but also acts as an oncogene in multiple 
malignancies[105]. Currently, both labels are thought to be inadequate in the WT1 
context, as, rather than describing the cellular function of WT1, they more accurately 
describe the effect of WT1 alteration in the varying contexts of cell type, 
differentiation status, presence of other gene alterations and microenvironment. On 
this account, WT1 probably can be best described as a chameleon-like gene, 
functioning as either a tumor suppressor gene or an oncogene, depending on the 
cellular context [106].  
The WT1-gene product encodes a transcription factor of the zinc-finger family 
(Figure 3) , which plays a key role in proliferation, apoptosis and organ 
development[107]. In adults WT1 expression is normally limited to the urogenital 
system, the central nervous system and to hematopoietic tissues, but pathological 
over-expression of the WT1 gene occurs in hematological malignancies and various 
types of solid tumors [103, 108-110].  
 
Figure 3: Schematic representation of the WT1 protein. The N-terminal domain comprises a 
dimerisation domain; a transcriptional activation and repression domain; and a putative RNA 
Recognition Motif (RRM). Alternative splicing of exon 5 and the amino acids KTS generates four 
main WT1 isoforms. [111] 
 
First evidence of WT1 involvement in leukemia was reported in 1990 by Call et 
al. [104] in a pre-B cell line, as well as by others, initially appointing WT1-
overexpression to 14-68 % of acute leukemia cells [112, 113]. Up to date WT1-
overexpression is considered to virtually occur in all subtypes of adult ALL and 
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AML [114]. Depending on the source, expression frequencies in AML range from 
67% up to 89% [115-117]. Elevated WT1-mRNA- levels are associated with short time 
transformation of MDS to AML [118] and also are a strong indicator of increased 
relapse frequencies after chemotherapy due to minimal residual disease [119, 120]. 
Interestingly, the majority of acute leukemias do not exhibit mutations of the WT1 
gene, suggesting that the wild-type protein may play an important role in 
leukemogenesis [121]. Mutation rates in AML comprise values ranging from 5-12 %, 
showing higher mutation frequencies in patients with younger age [122, 123].  
In vitro and in vivo evidence proved that humoral immune responses against the WT1 
protein can be elicited in patients with WT1-expressing hematopoietic malignancies 
[124]. The same group recently showed, that high values of naturally occurring anti-
WT1-antibodies are a strong predictor of longer survival in patients with MDS or 
MDS-derived AML[125] and are associated with favorable prognosis in non-small cell 
lung cancer (NSCLC)[126]. In contrast to differentiation antigens, which are mainly 
used as targets in melanomas and other solid tumors, WT1 is a crucial factor 
concerning the proliferation of the tumor. In fact, experiments using WT1-anti-sense 
oligonucleotides demonstrated reduction of proliferative capacity and differentiation 
of leukemic blasts and tumor cells in vitro [127]. Due to the functional relevance of 
WT1, the progression of WT1-negative tumor derivates, in the context of immune 
escape, seems unlikely. This is consistent with data generated in our institution, 
showing that loss or mutation of WT1 occurs in only one out of ten patients [128]. To 
date several MHC-class-I- as well as MHC-class-II-restricted peptides, binding to 
HLA-A1, HLA-A0201 and HLA-A2402 or HLA-DR04 and HLA-DR53, 
respectively, have been identified as T cell epitopes for WT1 (Table 4). 
MHC-subtype Epitope  Table 4: natural WT1-
derived CTL epitopes 
eliciting WT1-specific 
CTLs. 1, 2 These peptides 
elicit T cell responses in the 
context of two HLA 
subtypes: 1 the HLA-A201 
and the HLA-A2402 
subtype. 2 the HLA-DR4 
and the HLA-DR53 
subtype. According to Oka 
et al.[129], Asemissen et 
al.[130], Knights et al[131]. 
and Kobayashi et al.[132] 
HLA-A1 TSEKRPFMCAY (WT1317-327) 
HLA-A0201 
 
 
RMFPNAPYL (WT1126-134) 
SLGEQQYSV (WT1187-195) 
CMTWNQMNL1 (WT1235-243) 
HLA-A2402 CMTWNQMNL1 (WT1235-243) 
RWPSCQKKF (WT1417-425) 
HLA-DR0401 PQQMGSDVRDLNALL2 (WT1124-138) 
HLA-DR53 PQQMGSDVRDLNALL2 (WT1124-138) 
EDPMGQQGSLGEQQ (WT1247-261)  
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The first clinical vaccination trials using WT1 were initiated 2002 in our 
institution [93, 133, 134], as well as in the group of H. Sugiyama in Japan [2] and in 
the group of K. Rezvani in the USA [3, 135]. All trials showed high 
immunogenicity in terms of an induction of WT1-specific T cells, molecular 
efficacy and clinical efficacy of WT1-peptide vaccination. 
The Japanese design included 12 AML patients in CR and 2 MDS patients which 
were vaccinated with different amounts (0.3 mg; 1 mg and 3 mg) of an HLA-A24-
restricted WT1(235-243)-epitope emulsified in Montanide, while the American study 
included 5 AML patients in CR and 2 MDS patients who received an HLA-A201-
restricted WT1(126-134) -epitope in combination with an HLA-A201-restricted 
Proteinase-1 (PR1)(169-177)-epitope, Montanide and GM-CSF.  
In our institution, patients received 62.5 µg GM-CSF on days 1-4 and, on day 3, 0.2 
mg HLA-A0201-restricted WT1126-134 peptide admixed with 1mg KLH (Figure 4).  
 
Figure 4: vaccination scheme employed in the current clinical trial at our institution. Patients 
received GM-CSF on days 1-4 to chemotactically attract DCs to the injection site. On day 3 the 
WT1126-134 peptide, which competitively binds to MHC-class I molecules to be recognized by specific 
CTLs was injected. Together with the WT1 epitope, the whole protein KLH was administered, which 
is taken up pinocytotically by the DCs, internally processed and presented via MHC-class II 
molecules to deliver a WT1126-134 -independent CD4
+-helper cell co-stimulus at the site of vaccination. 
In our trial and as previously published, 17 AML-patients with active AML and 2 
MDS patients with refractory anemia with excess blasts (RAEB) and without further 
conventional treatment option received a median of 11 vaccinations. During 
vaccination course one complete remission (CR, 514 days) and 14 stabilizations of 
disease status (SD, 101 to 1682+ days) were observed, including 4 SD coincided by a 
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reduction of blast count of more than 50% and 3 SD displaying hematological 
improvement. Up to date, two patients are still in ongoing SD for more than 1600 
days and are vaccinated and monitored on a regular basis (Figure 5).  
 
Figure 5: Long-term monitoring of patient 22 (A) and patient 23 (B) during vaccination course. 
Both patients are in SD since treatment initiation ▲= vaccination; ▀= chemotherapy; ●= 
hemoglobin (mM); ■ WT1-mRNA. 
In addition, out of 8 AML patients in complete remission but at a high risk for early 
relapse, 4 patients exhibited an unexpected long progression-free survival with 10, 
17, 23 and 24+ months (so far unpublished results). In 52% of the patients with 
active leukemia, the WT1-mRNA level in peripheral blood (PB) decreased to at least 
one third compared to baseline at day 0. The number of patients with induced 
WT1128-134-specific T cells in PB increased from 28% at baseline to 52% in week 10 
(Figure 6), whereas WT1126-134-specific cytokine responses in patients increased from 
24% to 48% in the same time frame.  
 
Figure 6: Representation of WT1128-134-specific T cell frequencies in PB and BM during 
vaccination. Frequencies in PB increased from initial 28% at baseline to 52% in week 10 according to 
WT1-Tetramer staining. In BM, the actual site of the tumor, WT1128-134-specific T cell frequencies 
significantly mounted in week 18 (p=0.4). Positivity was determined as % WT1-Tetramer+ ≥ 0.3 
(mean + 2-fold standard deviation of healthy controls). Published by Keilholz et al. [93]. 
In AML patients in complete remission, the WT1-mRNA level in peripheral blood 
decreased in 57% of the patients. The number of patients with WT1128-134-specific T 
cell increased from 28% at baseline to 71% in week 10. As 42% of these patients 
already exhibited WT1126-134-specific cytokine responses at baseline, a vaccine-
induced cytokine response only could be observed in one additional patient. 
Introduction 
 29 
Considering the diverging numbers of the patients’ subsets, both collectives seem to 
display similar vaccine-related effects concerning a molecular and cellular response 
in PB, suggesting a broad therapeutic benefit of WT1126-134)-peptide vaccination. 
These data correlate well with the Japanese and American trials. The Japanese group 
observed an induction of WT1-specific T cells in 9 out of 13 patients in PB as well as 
a reduction of WT1-mRNA transcripts in 5 out of 14 patients in terms of a molecular 
response [2]. Similar results were published by Rezvani et al., observing an induction 
of a temporary WT1-specific T cell response in 5 out of 8 patients and a temporary 
molecular response in 3 out of 6 patients after a single administration of a WT1-
epitope combined with a PR1-epitope, Montanide and GM-CSF in their vaccine 
setting [3]. Nevertheless, in a current publication Rezvani et al. showed that repeated 
PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained 
high-avidity, epitope-specific CD8+ T cells in myeloid malignancies [135].  
These results represent preliminary evidence of immunological, molecular and 
clinical efficacy of WT1-peptide vaccination in asubset of patients. Despite these 
encouraging results and ongoing efforts in inducing TAA-specific T cells, objective 
clinical responses are not reliably induced [136]. As an explanation for the lack of 
clinical effectiveness in the presence of antitumor T cells, a variety of mechanisms 
have been subject of scientific dialogue and research: the induction of tolerance 
towards „self“-antigens and/or the extensive immune evasion of the tumor [137-139]. 
In most cases, the generation of an immune suppressive microenvironment by the 
tumor displays a major obstacle in eradicating the tumor. This can be effected by 
substrate deprivation or the secretion of chemo-attractants, leading to the migration 
and accumulation of e.g. immune regulatory cells (regulatory T cells,  myeloid-
derived suppressor cells (MDSC)) at the tumor site[140].  
Additionally and very characteristic for tumors derived from the hematopoietic 
system, the expression of immunomodulatory or apoptotic factors by the blasts may 
constitute a major obstacle for an effective immune response [141, 142].  
Briefly, if specific antitumor T cells are present and the tumor still progresses, one 
can logically deduce three main reasons: Impairment of the effector-function of T 
cells, the induction of immune regulatory cells and/or immune escape mechanisms of 
the tumor.f  
                                                 
f The author is aware that the immune system represents a complex and tightly cross-linked 
system, in which actio et reactio lead to reciprocal interplay of these mechanisms. 
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1.4 Immune evasion and tolerance 
The confrontation of the immune system to a new pathogen usually leads to one of 
three basic outcomes: early, complete expulsion of the foreign pathogen; 
overwhelming infection with failure of control; or persistence with potential long-
term carriage or induction of disease. It is the last scenario in which immune evasion 
takes place [143]. 
If we gaze at immunity in an evolutionary context, the organisms’ defensive 
resistance constitutes a formidable selection force on malignant cells or pathogenic 
agents. In this context, the main mechanisms of immune escape usually comprise 
dormancy (minimizing antigen expression), sequestration (occupying immune 
privileged sites), antigenic variation and counter mechanisms (see also section 1.4.1). 
On this account, microbial organisms as well as parasitic protozoa have coevolved 
with their hosts to overcome protective host barriers and, in selected cases, actually 
take advantage of innate host responses [144].  
Nevertheless, without immune evasive mechanisms, beneficial symbiosis, like the 
colonization of the gastrointestinal tract or on the skin by commensal bacteria 
(“normal microflora”) would not have taken place [145]. 
1.4.1 Tumor characteristics and immune escape 
Despite the beneficial effects of immune evasion in symbiosis, similar effects are 
able to impair tumor eradication: Tumors progress in individuals because they are 
able to overcome immune surveillance. In the context of evolution, the tumor has to 
adapt to a hostile environment to escape from rejection and elimination by the 
immune system. Its performance depends on the ability to modulate the specific 
immune response or to prevent recognition by the immune system. Different tumors 
react different to the immunological menace, but the mechanisms used can usually be 
classified to one of five main strategies (summarized in Table 5) [139, 146].  
However, as most of the current evidence of negative regulatory mechanisms has 
been acquired in the field of solid tumors, the role of the same or different 
mechanisms has been underexplored in hematologic malignancies. Due to the 
differential provenance and growth patterns of solid and hematologic malignancies, 
immune mechanisms explored in solid tumors may be used as guidelines, but 
awareness of variances in the repertoire of immune evasion in each entity may be 
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raised. Therefore, the understanding of the inhibitory pathways in hematological 
malignancies is of great importance in establishing successful cancer immunotherapy 
of leukemia patients in the clinic. 
 
Strategy Mechanism 
Impaired antigen presentation Mutation or downregulation of tumor antigens 
 Mutation or downregulation of MHC genes  
 Defects in antigen processing 
Immunosuppressive factors Cytokines (TGF-, IL-8, IL-10) 
 Prostaglandines 
Tolerance induction Anergy induction (PD-L1) 
 Immune deviation 
 Regulatory T cells (IDO) 
 T cell deletion 
Resistance to apoptosis Expression of anti-apoptotic molecules (PI-9) 
 Downregulation and mutation of pro-apoptotic molecules 
Counteraction Expression of death-receptor ligands (FasL, TRAIL) 
Table 5: Summary of the main cancer strategies used to interfere with immune surveillance. 
 
Interestingly, several escape mechanisms mimic or induce classical immunological 
processes to silence the immune response. Especially, in the context of leukemia, this 
effect is intensified due to the hematopoietic origin of the tumor, frequently resulting 
in expression of membrane-bound or soluble immunosuppressives as TGF-, PD-L1, 
IL-10, IDO, HMOX, CXCR4, VEGF and IL-8 or diminished sensitivity towards 
apoptosis by the expression of cytolysis-inhibitors like PI-9[5, 137, 147-152].  
1.4.2 Transforming-growth-factor beta  
Transforming growth factor β (TGF-β) is a regulative protein, controlling 
proliferation and cellular differentiation in most cells. First described in the early 
eighties [153] as initiator of anchorage-independent growth of epithelial cells, it was 
found to be a regulator of the cell cycle and to be critical for wound healing in 
physiological conditions.  
In the oncogenic context, it plays a dual role. It can serve as both, a suppressor and a 
promoter: TGF-β inhibits the growth of some cancers while stimulating growth in 
advanced cancers. Under normal conditions, TGF-β arrests the cell cycle at the G1 
stage to stop proliferation, induce differentiation, or promote apoptosis through the 
Smad- or non-Smad-pathways ( 
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Figure 7). The ransformation of a normal cell into a cancer cell can affect parts of the 
TGF-β signaling in a way that the regulative functions are shut down. These cancer 
cells than proliferate and induce proliferation in the tumor microenvironment by 
increasing their production of TGF-β. This causes immunosuppression and 
angiogenesis, which makes the cancer more invasive [154]. TGF-β also converts 
effector T cells into regulatory T cells and is also linked to TH17 development and 
function [155]. 
However, TGF- β is also known to 
suppress tumor growth. Lack of, or 
downregulation of TGF- β receptor or 
SMADs is often correlated to a worse 
prognosis and in several murine 
models deletion or downregulation of 
TGF- β signaling results in more 
malignant tumor phenotypes [156, 157]. 
The exact underlying mechanisms 
driving TGF- β to either promote or 
suppress tumor growth are not fully 
understood, but are in the focus of 
current investigations on the 
modulation of the host immune 
system by the tumor 
microenvironment. 
 
 
Figure 7: Transforming growth factor-β 
signaling. Binding of TGF-β to its receptors 
leads to the activation of the Smad complex 
which interacts with other DNA-binding 
transcription factors to regulate the transcription 
of target genes. Adapted from Ikushima et al. 
[158]. 
 
1.4.3 Programmed death receptor ligand 1  
Programmed death receptor ligand 1 (PD-L1, B7-H1, CD274) is one of two ligands 
binding the anergy receptor Programmed Death 1 (PD-1, see also section 1.5.2). 
Under normal conditions, PD-1/PD-L1 interactions contribute to the maintenance of 
peripheral tolerance to self-antigens. Ligation of PD-L1 with PD-1 has been 
described to negatively regulate cytokine production and proliferation of T cells [159], 
as well as driving T cells into an anergic state. The major mechanism of PD-1/PD-L1 
mediated T cell inhibition lies in the ability of the PD-1 receptor to recruit and 
activate intracellular phosphatases, which negatively regulate TCR signaling and 
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effector T cell responses. PD-L1 is broadly expressed in tissues and can also be 
found on almost all tumor entities. This fact leads to hypothesis that tumors escape 
from the host immune system by negatively interfering with tumor-specific T cell 
responses via the PD-L1/PD-1 pathway [160]. In accordance with this hypothesis, 
blockade of PD-L1 inhibits tumor growth or delays progression in multiple murine 
models [161] and PD-L1 expression on tumor cells correlates with a worse clinical 
outcome in several solid human malignancies [15, 162]. Despite its effects on 
hematopoietic cells, the role of PD-L1 in leukemia is only investigated marginally, 
and the few findings are controversial [163, 164]. 
1.4.4 Interleukin-10 
Interleukin-10 (IL-10), a type-II cytokine, is produced by monocytes and to a lesser 
extent by lymphocytes (primarily TH2, TH17 and Tregs) 
[165]. It is known to transmit 
pleiotropic effects in immunoregulation and inflammation, by down-regulating the 
expression of TH1 cytokines (e.g. IFN-γ, IL-2, TNF-α), MHC class II antigens and 
co-stimulatory molecules on macrophages. It also enhances B cell survival, 
proliferation, and antibody production.  
IL-10, acting through the JAK/STAT-pathways, has also been associated with tumor 
progression: Besides the capacity of IL-10 to induce immune-modulatory cells, the 
amount of tumor-derived IL-10 correlates with disease-severity and prognosis in 
many tumors [166]. Due to its biological function, IL-10 serves as a potent inhibitor of 
antigen-presentation, mainly by down-regulating MHC-class II and the interference 
with the CD28-pathway. This results in T cell anergy [167], but only in T cells that 
need co-stimulation due to low TCR-triggering. As TAAs do usually not represent a 
strong trigger and can additionally be down-regulated in an immune evasive context, 
tumor-specific T cells are potentially affected.  
1.4.5 Indoleamine-2, 3-dioxygenase 
Indoleamine-2,3-dioxygenase (IDO) catalyzes the limiting step of tryptophan 
catabolism along the kynurenine pathway (Figure 8) [168]. It has been described to 
play a role as a normal, endogenous mechanism of peripheral tolerance and 
immunosuppression in a number of immunological privileged sites such as maternal 
tolerance towards the fetus, the brain and the eye [169]. IDO can be expressed by 
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various cell types as response to inflammation, but it seems that some subsets of 
APC preferentially express IDO after humoral or cellular stimulation. 
Still, IDO-competency of these 
cells is dependent of additional 
factors, regulated by maturation 
and activation signals [170]. In the 
context of immune tolerance, and 
as with any beneficial factor, 
tumors have adapted to express 
IDO to impair tumor specific 
immune responses [171, 172]. IDO 
expression on tumors occurs 
constitutionally, or after induction 
by inflammatory mediators, such 
as IFN-γ.  
  
Tryptophan
Kynurenine Kynurenic acid
3-hydroxyanthranilic acid
Quinolinate
3-hydroxykynureine Anthranilic acid
IDO
 
Figure 8: flow-chart of the kynurenine pathway. 
IDO-upregulation leads to local tryptophan-depletion 
at the tumor site and inhibits proper T cell function 
The processing of tryptophan by IDO leads to two immunosuppressive effects, a 
reduction in local tryptophan and an increase in tryptophan-metabolites. The 
deprivation of tryptophan causes cellular stress and anergy in T cells, due to impaired 
tRNA-charging and in consequence impaired translation. In contrast, the increase of 
some tryptophan derivatives causes cell cycle arrest and apoptosis in T cells [173]. 
Furthermore, in an hematological context, bone marrow (BM)–derived mesenchymal 
stem cells (MSCs) expressing IDO have the capacity to suppress T cell responses to 
autoantigens and alloantigens [174]. In the case of AML, data demonstrated functional 
expression of the active form of IDO protein, resulting in the inhibition of T cell 
responses through the expansion of regulatory T cells [175]. 
1.4.6 Heme-oxygenase 1 
Heme-oxygenase-1 (HO-1),  a highly conserved molecule across almost all forms of 
life, catalyzes the first, rate-limiting step in the oxidation of heme, producing 
equimolar quantities of carbon monoxide (CO), iron ions (Fe2+) and biliverdin [176]. It 
participates in maintaining cellular homeostasis and plays an important protective 
role in the tissues by reducing oxidative injury, attenuating the inflammatory 
response, inhibiting cell apoptosis, and regulating cell proliferation. Many data 
suggest that overexpression of HO-1 may defend tissues and organs from immune-
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mediated injury, either through protection against oxidative damage or via a local 
immunomodulatory influence on infiltrating inflammatory cells [177].  
In contrast to its isoformes HO-2 and HO-3, HO-1-expression is inducible and higher 
levels of HO-1 are detectable in tumors, if compared to the surrounding tissue [178]. 
Interestingly, it seems to be tumor dependent, whether the tumor itself or tumor-
infiltrating macrophages induce the expression of HO-1. In the context of immune 
evasion, the biological function of HO-1 prevents the fast proliferating tumor to 
suffer from oxidative stress[179]. Simultaneously, elevated HO-1 levels, i.e. the 
increased concentration of CO, have anti-proliferative effects in T-lymphocytes, 
resulting in diminished efficacy of tumor-specific T cells [180].  
Additionally to its anti-oxidative action, HO-1 can also affect cell viability by 
blocking apoptosis and lead to a considerable resistance of tumors to 
chemotherapeutic treatment [181, 182].  
1.4.7 CXC chemokine receptor 4 
CXC chemokine receptor 4 (CXCR4, also called fusin) is an alpha-chemokine 
receptor specific for stromal-derived-factor-1 (SDF-1), enhancing chemotactic 
activity for lymphocytes upon ligation. CXCR4 gained prominence due to its 
employment by HIV to infect CD4+ T cells [183]. 
The binding of CXCL12 to CXCR4 initiates divergent signaling pathways which can 
result in a variety of responses such as increased intracellular calcium-release and 
gene transcription leading to enhanced chemotaxis, cell survival and/or proliferation, 
increase [184]. 
In various types of cancer, including leukemia and breast cancer, CXCR4 has been 
identified to be a prognostic marker, mainly up-regulated in metastasis, triggering 
enhanced signaling and trafficking [185]. In AML, the SDF-1/CXCR4 pathway is 
responsible for the retention of leukemic blasts in the bone marrow [186], in which 
tissue specific factors, such as SDF-1 and interleukin 6 (IL-6) supplementary 
mediate, survival, and proliferation of tumor cells, providing a favorable and 
prosperous tumor-microenvironment.  
1.4.8 Serpin peptidase inhibitor, clade B (ovalbumin), member 9  
Serpin peptidase inhibitor, clade B (ovalbumin), member 9 (SERPIN B9 or PI-9) is a 
potent intracellular inhibitor of human granzyme B and is broadly distributed among 
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several tissues. It is present at elevated and constant levels in CTLs and APCs, as 
well as in many endothelial cells and at sites of immune privilege [187, 188], pointing to 
an immune modulatory function of this protein.   
Induction of PI-9 expression is mainly triggered by IFN-γ and the Hypoxia Inducible 
Factor 2 (HIF-2), but also lipopolysaccharide (LPS) and interleukin-1β (IL-1β) in 
inflammation, as well as estrogens are known to contribute to PI-9 expression [189, 
190]. In cells that express PI-9 and granzyme B (e.g. CTLs, NK-cells), intracellular 
serpins are thought to provide an important mechanism for the cell to evade death 
caused by the release of compartmentalized cytolytic proteases, that may leak into 
the cytosol during their storage in cytotoxic granula, or during the degranulation of 
the latter as the CTL executes its apoptotic functions [191]. 
There is evidence that ectopic PI-9 expression in tumor cell lines can protect against 
the cytolytic effects of granzyme B and perforin [192], and high levels of PI-9 are 
associated with a poor therapeutic response and prognosis in lymphomas and 
melanomas [193]. The association with hematopoietic tissue makes PI-9 an interesting 
candidate for evaluation of immune evasion in AML.  
1.5 T cells and functional inhibition  
T cell functions can be divided into three parts: activation, killing and regulation. 
Each of these processes can therefore be targeted to inhibit proper effector-functions 
of T cells, including constrained or lacking cytokine- or perforin-production or 
transformation of the T cell into an anergic state [194, 195]. These functions can be 
attributed to different subsets of T cells, which can be characetrized phenotypically: 
The classical approach uses the expression of the surface antigens CD4 and CD8 to 
segment CD3+ cells in two major functional subpopulations: 
T cells sharing the CD4 surface antigen are classified as helper T cells (mainly TH1, 
TH2 and TH17) and if activated, proliferate and secrete cytokines that provide 
essential co-stimulatory signals for activation and differentiation of cytotoxic T cells 
(CTLs), B-cells and macrophages for a complete immune response.  
CD8 is a common feature of CTLs which are responsible to lyse abnormal cells e.g. 
virally-infected, transformed or transplanted cells. The specific recognition via 
MHC-class-I/TCR interaction of a target cell by a CTL usually leads to induced 
apoptosis of the target cell, mostly via one of two mechanisms:  
 
Introduction 
 37 
a.) Induction of apoptosis via cytotoxic granula, modified lysosomes, that 
contain cytotoxic effector proteins, as perforin, granzyme and granulysin, 
which release proapoptotic pathways in the target cell, or 
b.) Through the activation of death-receptors, like FasR und TRAIL-R, 
subsequently inducing proapoptotic signal cascades. This mechanism, in 
contrast to perforin-mediated apoptosis, is mainly used to lyse pathogen-
specific lymphocytes after a cured infection to limit further proliferation.  
1.5.1 T cell subsets, functionality and homing 
As most cells during their live cycle, T cells traverse different phases of forming and 
function. This developmental process is strongly associated with the kind of 
challenge the cell experienced and is accompied by phenotypic transformations.  
The actual downstream process of T cell transformation is currently subject of a 
controversial discussion, implementing models of linear and divergent pathways of T 
cell differentiation [196-199]. However, the differential expression of four molecules, 
CD45RA, CCR7, CD27 and CD28, is widely accepted to distinguish between 
numerous subsets of “resting” (meaning cells that are not involved in any infection 
phase) T cells. According to this characterization, T cells are divided into naïve, 
effector(TEFF), effector memory (TEM), central memory (TCM) and highly 
differentiated subpopulations [200]. After primary contact to an antigen, naïve T cells 
differentiate into effector cells, traveling to the site of infection or settings of active 
antigenic stimulation (e.g., primary viral infection, vaccination), respectively. TEFF 
are able to eliminate viruses or tumors by different effector functions as mentioned 
above. The effector phase of the response is short, with a rapid expansion of antigen-
specific T cells and pathogen clearance. The expanded effector cells undergo a 
contraction phase, while approximately 5% to 10% of antigen-specific cells are 
maintained to establish a memory pool and provide long-term protection from a 
secondary challenge by the same pathogen.  
The functional requirements mirror the phenotypic transformation: As the 
interactions of different subsets of immune and non-immune cells at defined sites are 
required for the efficient function of the immune system, the ability of these cells to 
actively migrate to and within tissues is regulated by the expression of different 
chemotactic receptors. 
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Figure 9: Maturation-process within the major memory T cell subsets in humans. T cell 
differentiation can be modelled as a linear process, in which cells progressively gain functionality 
with further differentiation, until they reach the stage that is optimized for their effector function (such 
as the production of different cytokines). Consecutive antigenic stimulation can lead to progressive 
loss of memory potential, which is accompied by reduced CCR7-expression as well as cytokine 
production, resulting in terminally differentiated T cells that only produce IFN-γ and are short-lived. 
Figure adapted and modified from Seder et al. [8] 
 
One of these receptors, CC-chemokine receptor 7 (CCR7) is associated with the 
subpopulations’ potentials to establish a long-term memory [8] (Figure 9) and is also 
essentially involved in homing of various subpopulations of T cells (naive T cells, 
TCM cells and Tregs) as well as antigen-presenting dendritic cells (DCs) to the lymph 
nodes (Figure 10). For instance, naïve T cells, which are CCR7+, migrate into 
secondary lymphoid organs (SLOs), including peripheral lymph nodes, Peyer's 
patches and the spleen to first encounter cognate antigen and become activated [9]. In 
contrast, human TEM do not express CCR7 but display characteristic sets of 
chemokine receptors and adhesion molecules that are required for homing to sites of 
inflammation. 
 
Figure 10: The multi-step process of homing to the lymphnodes. Homing T cells emigrate from 
the blood to peripheral lymph nodes in a multistep process, consisting of tethering and rolling, CCR7-
mediated activation, firm arrest and transendothelial migration. Figure adapted from Förster et al [201]. 
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In the human system, the antigen-experienced cells have been divided into central 
memory- and effector memory-subsets based on two distinct criteria: (a) the absence 
or presence of immediate effector function and (b) the expression of homing 
receptors that allow cells to migrate to secondary lymphoid organs versus non-
lymphoid tissues [199]. TCM express the lymph node homing receptors L-selectin and 
CCR7 and, like naive T cells, are well represented in all SLOs. 
TCM have higher sensitivity to antigenic stimulation, are less dependent on co-
stimulation, and up-regulate CD40L to a greater extent, thus providing more 
effective stimulatory feedback to DCs and B cells than do naïve T cells. TCM have 
little or no effector function, but are able to readily proliferate and differentiate to 
effector cell upon antigenic encounter. As indicated by the nomenclature, TEM exhibit 
increased and rapid effector functions in terms of perforin loading and cytokine 
response to antigenic stimulation [202].  
1.5.2 T cell exhaustion and anergy 
Due to its high potency, the immune system has to be strictly regulated to avoid 
“collateral-damage” to unaffected cells and tissue. The concept of immune 
checkpoints, a series of factors that limit an ongoing immune response, has attracted 
considerable interest in cancer immunotherapy [6, 7]. According to this concept, the 
activity of peripheral T cells can be modified by positive and negative regulatory 
receptors leading to exhaustion or anergy if bound by the corresponding ligand. 
Multiple modulators are able to suppress exaggerated reactions of CTLs, a pathway 
usually used after pathogen-eradication. The most prominent of these regulators are 
part of the CD28/CTLA-4-family [5, 203]: CD28 and the cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) are expressed on T cells to bind to B7 family 
members expressed on antigen presenting cells, but result in different reactions: 
While the ligation of CD28 to the corresponding receptors, B7-1 or B7-2, facilitates 
T cell activation and promotes T cell expansion and differentiation [204], the ligation 
of CTLA-4 to the same receptors results in inhibition of TCR and CD28 mediated 
signals[205] (Figure 11).  
Several more members of the B7-CD28-family have been recently identified and can 
be correlated to the development or maintenance of immune tolerance. Recent 
investigations concerning this subject showed that multiple negative regulatory 
mechanisms appear within the tumor microenvironment to potently inhibit even 
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strongly primed antitumor T cell responses. The most common inhibitory 
mechanisms not provoked by the tumor, seem to be T cell anergy due to poor co-
stimulation by tumor cells, suppression of conventional T cell function by regulatory 
T cells or other regulatory cell types, and engagement of Programmed Death-1 
receptor on activated T cells with PD-L1.  
 
 
Figure 11: Influence of immune checkpoints on the proliferative capacity of T cells. Besides the 
recognition of the corresponding MHC/peptide complex, a T cell needs additional trigger like CD28 
activation to initiate cytokine production and proliferation. Consecutive activation of the T cell 
induces the expression of negative regulators, e.g. PD-1, binding to B7-H1 and CTLA-4, 
competitively binding to the same ligands as CD28. Activation of these regulators initiates signals that 
have opposite effects to those of CD 28/TCR activation and restrict proliferation, thus driving the T 
cell in an anergic state. Current immune checkpoint therapies target these interactions by the 
administration of interfering antibodies, resulting in a blockade of immune suppression. Figure 
adapted from Charles G. Drake [206]. 
 
First identified as a gene up-regulated in a T cell hybridoma undergoing cell death 
([203]), PD-1 is an immunoinhibitory receptor of the immunoglobulin (Ig) superfamily, 
sharing approximately 23% AA sequence homology with CTLA-4. PD-1 is 
expressed by chronically activated T cells, B cells, and myeloid cells [207]. A wider 
distribution of PD-1 than the predominantly T cell-expressed surface molecules 
CD28 and CTLA-4 suggests a more diversified role in immune regulation. The 
variety of immune diseases displayed by PD-1 knockout mice[208, 209], as well as the 
association of increased viremia in patients with chronic HIV[210, 211] and HCV[212] 
infections with high expression of PD-1 indicate a critical role of PD-1 in 
lymphocyte homeostasis. 
The engagement of PD-1-with one of its ligands, PD-L1 or PD-L2, results in 
impaired T cell proliferation and reduced cytokine production [159]. In the context of 
tumor therapy, it is important to notice, that expression of PD-L1 is reported on 
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many entities of human tumors, including AML [213], as well as on tumor-associated 
DCs [214]. Interestingly, although a lot is known about the expression of PD-L1, only 
rudimentary information is available on the pattern of PD-1 expression in AML and 
its direct implications on phenotypic and functional characteristics on tumor 
infiltrating T lymphocytes (TILs).  
1.6 Immune regulatory cells 
1.6.1 Regulatory T cells 
The third T cell function – regulation – can not be attributed to a distinct T cell 
compartment. So called regulatory T cells (Tregs) derive in most cases from the CD4
+ 
subpopulation, but CD8+ T cells displaying regulatory functions have been described 
recently [12, 215]. 
 
Figure 12: Basic suppressive mechanisms used by Treg cells. a)  Inhibitory cytokines b)  Cytolysis 
c)  Metabolic disruption d)  Modulation of DC maturation and/or function. Adapted from D. A. A. 
Vignali et al. [11]  
 
While Treg activity is usually required for normal immune homeostasis, dysregulation 
of their numbers can induce autoimmunity or aid in the pathogenesis of disease, e.g. 
systemic lupus erythematosus, rheumatoid arthritis or psoriasis. Phenotypically, 
CD25+CD127dim- or CD25+FoxP3+- expression actually are the state of art to 
discriminate Tregs from classical T cells. Regulatory T cells do not proliferate in 
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response to antigen binding but prevent the activation of helper and cytotoxic T cells, 
i.e. they exhibit regulative functions to limit the extent of immune activation (Figure 
12). Treg-mediated immunosuppression has also emerged as a crucial mechanism of 
tumor evasion, which is thought to potently contribute to the observed lack of 
responses to immunotherapy in cancer patients [216, 217]. 
Treg can suppress CD4
+ and CD8+ T cell proliferation and the production of effector 
cytokines regardless of TCR specificity. [215, 218] This is mediated, at least in part, by 
inhibition of IL-2 transcription within the target cell. Tregs constitutively express 
CTLA-4[219] and secrete inhibitory TGF-beta and IL-10.[220, 221] Treg-activity requires 
direct contact with the target T cell, although the molecular mechanism for 
suppression is not clear.  
1.6.2 Myeloid-derived suppressor cells 
Myeloid-derived suppressor cells (MDSCs) are a phenotypically heterogeneous cell 
population that includes mature myeloid cells, such as granulocytes, 
monocytes/macrophages, and DCs, as well as immature myeloid cells (IMCs).[222] 
Their presence has been observed in most cancer patients, where they are induced by 
various factors produced by tumor cells and/or by host cells in the tumor 
microenvironment, and are considered a major contributor to the profound immune 
dysfunction of most patients with sizable tumor burdens [222, 223]. Limited efficacy 
of current vaccination strategies is also thought to be partly attributed to 
MDSCs [10, 224].  
Features that are common to all MDSCs are their myeloid origin, their immature 
state and their ability to suppress T cell responses by limiting T cell function to cell-
surface receptors and/or through the release of soluble mediators with short half-
lives. Therefore, the definition of MDSCs occurs rather on their biological activity 
than on their phenotype. Nevertheless, there have been phenotypic approaches to 
characterize this heterogeneous population: human MDSCs are usually defined as 
CD14-CD11b+ cells that express the myeloid marker CD33 but neither MHC-class-
II, co-stimulatory molecules, or other mature myeloid and lymphoid markers [223]. 
In healthy individuals, IMCs constitute approximately 0.5% of peripheral blood 
mononuclear cells. In contrast to healthy individuals, where IMCs quickly 
differentiate into mature granulocytes, macrophages or dendritic cells, partial 
blocking of IMC maturation in pathological conditions (e.g. cancer, various 
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infectious diseases, sepsis and trauma) results in the expansion and accumulation of 
this population (Figure 13) [222]. 
 
Figure 13: The origin of MDSCs. a) Immature myeloid cells (IMCs) are part of the normal process 
of myelopoiesis, controlled by a complex network of soluble factors, including cytokines and cell-
expressed molecules. b) Normally, IMCs migrate to different peripheral organs, where they 
differentiate into macrophages, dendritic cells or granulocytes. Factors that are produced during acute 
or chronic infections, trauma or sepsis and in the tumor microenvironment promote the accumulation 
of IMCs, prevent their differentiation and induce their activation. Figure adapted from D. I. 
Gabrilovich et al. [222].  
If activated, IMCs up-regulate the expression of immune suppressive factors, such as 
arginase 1 and nitric oxide synthase (NOS2), resulting in an increased production of 
nitric oxide (NO) and reactive oxygen species (ROS). The increased activity of 
arginase 1 in MDSCs leads to enhanced L-arginine catabolism, which depletes this 
non-essential amino acid from the microenvironment. The deprivation of L-arginine 
then inhibits T cell proliferation through several different mechanisms, mainly 
affecting the expression of CD3 and cell cycle regulators [225, 226]. 
NO suppresses T cell function through various different mechanisms that involve the 
inhibition of JAK3 and STAT5 functions in T cells [227], the inhibition of MHC class 
II expression  and the induction of T cell apoptosis [138]. Generally, MDSC have been 
shown to contribute to the inhibition of NK cell cytotoxicity [228], the perturbation of 
lymphocyte trafficking [229] and the induction and accumulation of Treg cells 
[230, 231]. 
Interestingly, a recent publication shows evidence, that there exists a co-dependent, 
or, as the authors entitle it, a retaliatory relationship between T cells and MDSC in 
that MDSC suppress T cell activation, but, once activated, T cells are able to mediate 
MDSC apoptosis via the Fas/FasL-pathway [232], providing a new and surprising 
perspective to an intricate suppressive mechanism. 
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1.7 Immune assays / Immunomonitoring 
The detection and enumeration of disease-specific T cells and their antigenic 
specificity are of major importance in T cell immunology and its application in 
targeted therapy. However, the valid enumeration of spontaneous and therapy-
induced T cell responses remains challenging, as generally low frequencies of tumor-
specific T cells (range from 1x104 to 1x105) request sensitive, ccurate and 
reproducible detection methods. Especially in the context of immune monitoring, 
where the quantification and the assessment of functionality of specific T cells are 
routinely performed, standardized and accurate assays represent a major pre-
requisite [233]. 
On this account, fluorescent peptide/MHC-multimers [234] are widely used to directly 
identify, quantificate and phenotype antigen-specific T cells by flow-cytometry. 
Their application in combination with fluorescence-activated cell sorting (FACS) 
and/or magnetic-activated cell sorting (MACS) even allows purification of antigen-
specific T cells. Admittedly, peptide/MHC-multimer do not deliver information 
concerning effector functions of the targeted T cells, requiring additional functional 
or combined assays. 
Current functional assays, including the enzyme-linked immuno spot technique 
(ELISPOT)[235] as well as intracellular-cytokine flow-cytometry (ICC), are both able 
to detect an antigen-induced cytokine response on the single-cell-basis.  
The ELISPOT-assay represents a sensitive[236, 237] and reproducible[238-240] technique 
with a broad range of target molecules like IFN-γ, TNF-α, TGF-β, Granzyme B, IL-
2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, GM-CSF, Fas-Ligand and MMP-1, 
which has been adapted for high-throughput processes [241]. However, it lacks 
information on the phenotypic composition of the tested samples, which, in contrast, 
represents a benfit when using the ICC-technique. Current flow-cytometers are able 
to detect up to 20 parameters, allowing defined and simultaneous characterizations 
on the phenotypic and functional analysis of the investigated T cells[242], covering 
multiple features as the memory/effector status, the proliferative capacity[243], the 
activational state, the cytokine profile as well as the cytolytic function[244]. In 
addition, ICC can be combined with peptide/MHC-multimer analyses. Yet, the 
increasing amount of available dyes exacerbates the optimal selection of 
fluorochrome-combinations as well increases interpretative variances between 
different cytometer-facilities [245]. On this account, current multi-center-initiatives to 
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harmonize ELISPOT-, ICC- and MHC-multimer-assays have been established to 
facilitate future data comparison [246-248].  
 
Nevertheless and despite these convenient characterizational approaches, functional 
analyses can not be circumvented when analyzing T cell reactivity and immunity. 
Therfore, the functional and cytotoxic capacity of CTLs is usually determined by 
cytolytic assays. 
Effector cell-mediated cytolysis is usually detected by alterations of plasma 
membrane permeability and integrity and the resulting release of components into the 
supernatant or the uptake of dyes that are normally excluded by viable cells. Assays 
focusing on the release of tracer reagents frequently used to contain radioactive 
isotopes, e.g. 51Cr, 75Se or 3H. As the use of these products is potentially hazardous 
and includes special training, the detection of cell-mediated cytolysis in a more 
convenient way represents a certain requirement in scientific research. Therefore, 
several non-radioactive tracer assays have been developed, but the indirect results 
often limit the accuracy of these measurements, especially for antigens with low 
immunogenicity [249]. Additionally, with growing knowledge regarding apoptosis, the 
disadvantages of these assays grew as well. For instance, early phases of apoptosis 
don’t affect membrane permeability. Altenative assays therefore focus on structural 
changes occurring during those stages. One compound that translocates from the 
inner to the outer leaflet of the plasma membrane is the lipid phosphatydilserine 
(PS), which can easily be detected by extracellular staining with fluorochrome-
coupled AnnexinV[250]. In combination with the DNA-intercalator propidium-iodide 
(PI), dead cells can then easily be separated from apoptotic cells. Nevertheless, the 
use of PI also requires carefull handling and excessive rinsing of the used ctometers. 
Actually, several innovative fluorescent dyes have been introduced and are now 
widely used [251, 252] among the scientific community.  
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2 Objectives 
The capacity of T cells to induce an immune response, against foreign pathogens or 
cancerous cells represents the basis of immunity. Successful cancer immunotherapy 
therefore relies on the quantitative as well qualitative effector function of pathogen-
specific T cells. Nevertheless, the tumor microenvironments as well as the tumor 
cells themselves are able to evade immunosurveillance and/or to impair proper T cell 
responses. It seems evident, that a loss of function of the host immune system is an 
important factor limiting the success of cancer immunotherapy.  
The foregoing study investigated the immunogenicity of Wilms’ tumor gene product 
1 (WT1)-peptide vaccination in WT1-expressing acute myeloid leukemia (AML) 
patients without curative treatment option. Despite the first immunologic, molecular, 
and preliminary evidence of potential clinical efficacy in AML patients, only in a 
few cases long-lasting responses could be documented. It is known that enduring 
efficacy of cancer vaccines may be limited due to immune escape mechanisms.  
As analyses for loss or mutations of the WT1 epitope or epitope flanking sequences 
that may impair proper T cell recognition or epitope presentation turned out negative, 
this work was initiated to reveal further potential immune escape mechanisms. We 
chose to work on three front lines: Investigations of immune modulatory counter-
attack-mechanisms of the tumor, functional deficiencies of the T cell compartment 
and the presence of immune regulatory cells (summarized in Figure 14).  
 
Figure 14: Outline of the targeted factors in this work which may interfere wit vaccine efficacy.  
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3 Material and Methods 
3.1 Patients 
3.1.1 Patients characteristics and vaccination regimen 
The analyses were performed in a subgroup of patients with relapsed AML, first 
remission AML at high risk of relapse, or untreated AML, who were included in a 
phase II vaccination study  with WT1 peptide, KLH and GM-CSF[93].   
 
Patient Age FAB Karyotype Vacc. Clinical response PFS 
  1 66 M4 Normal 12 CR 17 months from week 8 on 514 
  2 67 M2 46 XX; t 11,q23 12 Persistent CR 36+ month 978 
  3 82 M2 Normal 4 SD 3 months 136 
  5 72 M2 Normal 6 PD after # 2 37 
  6 74 M1 47 XX +11/46 XX (23) 9 SD for 4 month 201 
  7 67 M2 46 XY/47XY,+8 9 Relapse after 4 month 128 
  8 45 M7 Normal 4 PD after # 4 50 
  9 68 M5B Normal 12 Relapse after 10 month 310 
10 73 sAML Normal 12 SD and erythr. resp. for 7 months 262 
11 63 sAML Normal 18 SD for 4 month 101 
12 80 M4 Normal 8 SD for 3 month from week 10 144 
13 20 M4 Normal 5 Relapse after 2 month 68 
14 59 M4 Normal 4 PD after #4 29 
15 32 M2 47XY+; t3;21 5 Relapse after #5 57 
16 65 M4 Normal 12 SD for 2 months/PD after week 18 134 
17 67 RAEB II Normal 24 SD 10 months 339 
18 61 sAML Normal 11 SD 5 months 142 
19 69 RAEB II Normal 10 SD for 2 months 69 
20 75 sAML Comple X 10 SD for 2 months 132 
21 82 M4 Normal 11 SD for 4 months 149 
22 65 M2 Normal 15+ Ongoing remission since 1682 
23 58 M2 Normal 14+ SD ongoing since 1668 
24 72 sAML Normal 13+ Initial PD, SD 2 months 504 
25 73 sAML Normal 11 Relapse after 5 months 147 
26  sAML 46XX (del5) 11+ SD for 4 months 99 
Table 6: Patients characteristics and clinical response.  
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Vaccines were injected intradermally and subcutaneously, approximately 10 cm 
distal of the right groin. One vaccination comprised four days of 62.5 µg GM-CSF 
(Leukine, Berlex, Seattle) and on day three 0.2 mg of the HLA-A201-restricted 
WT1.126-134 epitope peptide RMFPNAPYL (Clinalfa, Switzerland) admixed with 
1mg KLH (Immucothel, biosyn, Germany).This clinical trial had been approved by 
the Institutional Ethics Committee, and written informed consent was obtained from 
all patients and healthy subjects before sampling.  
3.1.2 Sample collection 
Sera and heparinized peripheral blood samples were obtained from each patient at 
different time points. Serum was frozen at -20°C and peripheral blood mononuclear 
cells (PBMCs) were isolated by density gradient centrifugation using Ficoll-Hypaque 
and cryopreserved.  
3.2 Healthy controls 
Buffy coats were obtained from blood donors from DRK. PBMCs were isolated 
using a density-gradient (Ficoll Hypaque) and cryopreserved. Lymphocytes were 
HLA-typed and tested for reactivity towards Influenza A, CMV and EBV. 
3.3 Human cell lines  
line ATCC-number DMSZ-number Disease Cell type Reference 
HL-60 CCL-240 ACC 3 AML promyeloblast [253] 
K-562-A2* CCL-243 ACC 10 CML erythroblast [254] 
Molt-4 CRL-1582 ACC 362 ALL T lymphoblast [255] 
TF-1 CRL-2003 ACC 334 erythroleukemia erythroblast [256] 
THP-1 TIB-202 ACC 16 AML monocyte [257] 
UT-7 n.a. ACC 137 AML megakaryocyte [258] 
Table 7: Summary of available and used human leukemic cell lines. The listed cell lines were 
purchased via the American Type Culture Collection (ATCC) or the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (DMSZ, German Collection of Microorganisms and Cell 
Cultures). * K562-A2 is an HLA-A2 transfected cell line based on K562. The provided information in 
this table therefore applies to the original cell line.  
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3.4 Antibodies and staining reagents 
Antibody Conjugate Manufacturer  Antibody Conjugate Manufacturer 
CCR7 - BD  CD86 FITC BD 
CD107a PE BD  GAM Biotin Southern biotech 
CD11b PE-Cy7 BD  GAM PE BD 
CD127 FITC eBioscience  HLA-A2 Alexa647 AbD Serotec 
CD137 APC BD  HLA-DR PE BD 
CD14 PerCP BD  HO-1 FITC Abcam 
CD14 APC BD  IFNy FITC BD 
CD19 FITC Coulter Biotech  IgG Peroxidase Nordic Laboratories 
CD25 PE BD  IgM Peroxidase Nordic Laboratories 
CD274 APC BD  Il-2 APC BD 
CD3 AmCyan BD  Il-2 Biotin BD 
CD3 FITC Coulter Biotech  INDO PE USbiological 
CD3 PerCP BD  PD1 PE BD 
CD33 PE-Cy7 BD  PI-9 APC-H7 Santa Cruz 
CD34 PE-Cy7 BD  SAV PerCP BD 
CD4 PE-Cy7 BD  SAV 750 Invitrogen 
CD56 FITC BD  TNFa PE-Cy7 eBioscience 
CD8 APC-H7 BD  ViVid PacificBlue Invitrogen 
CD80 FITC BD  WT1 - Dako 
Table 8: Register of antibodies and the corresponding distributors. 
3.5 ELISA to detect anti-KLH immunoglobulins 
For the detection of KLH-specific antibodies (IgM- and IgG-subtypes), 96-well 
plates were coated with KLH (50µg) for 1h and washed twice with aqua dest. 
Blocking was performed with BSA for 30 min followed by two washing steps. Plates 
were then incubated with sera (diluted 1:10 in PBS) for 30 min and washed twice 
again. Consecutively, peroxidase (PO) -conjugated anti-IgM or anti-IgG antibodies 
(Nordic Immunological Laboratories, Eindhoven, Netherlands) were allowed to bind 
KLH-specific Igs for 30 min. After two washing steps, 100 µl of the peroxidase 
substrate 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid (ABTS)[259] 
(Millipore, Schwalbach/Ts., Germany) was allowed to react with remaining PO-
conjugates. Extinction was measured at λ = 550 nm. Positivity was determined as the 
mean value of three healthy donors increased by the triple standard deviation. As 
positive control, a serum mix of orally with KLH immunogenized patients was 
kindly provided by J. Maul.   
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3.6 Western-Blot to detect anti-hGM-CSF immunoglobulins 
Sera of patients were tested for anti-GM-CSF antibodies (isoformes IgG and IgM) 
via Western-Blot as previously described [260]. Briefly, GM-CSF (Leukine; Berlex, 
Seattle, WA, USA) was run on a 15% SDS-PAGE and transferred to Hybond-C 
nitrocellulose membrane (Amersham Biosciences, Freiburg, Germany). After 
stripping, the membrane was blocked overnight with skimmed milk (5% (Milupa, 
Friedrichsdorf/Ts., Germany) in PBS with 0.01% Tween-20) and incubated with 
serum for 1 h, washed twice with PBS-T and probed with Peroxidase-conjugated 
antibodies to human Igs (Nordic Immunological Laboratories). Development was 
performed with a DAB-System (Vector Laboratories).   
3.7 MTT-Assay 
For the detection of neutralizing antibodies to GM-CSF we performed a MTT-Assay 
(Cell Proliferation Kit I (MTT), Roche, Basel, Switzerland). Culture medium 
containing hGM-CSF (0.5 ng/ml) was preincubated with patients’ sera in 96 well, 
flat bottom microplates. TF-1 cells were added at a concentration of 5 × 103 
cells/well in 50 μl culture medium and incubated for 48 h in a humidified atmosphere 
(37°C, 5% CO2). After the incubation period, 10 μl of the MTT labeling reagent 
(final concentration 0.5 mg/ml) were added to each well. The microplate was then 
incubated for 4 h, before 100 μl of the solubilization solution was put into each well. 
After overnight incubation the plate was checked for complete solubilization of the 
purple formazan crystals and photospectrometrically measured at 650 nm using an 
ELISA reader. 
3.8 Cell culture 
3.8.1 Passaging of human cell lines 
Human leukemic cell lines were cultured in RPMI medium (PAA, Linz, Austria) 
supplied with FCS (10%, PAA). Depending on the cell line and according to the 
references, specific adjuvants as additional FCS, GM-CSF or gentamycin were 
added. The cell lines were initially seeded in a 6-well plate (Sarstedt, Nümbrecht, 
Germany) and transferred into a 100 ml culture flask (BD Falcon, Franklin Lakes, NJ 
USA) after 2 days. Culture medium was then consecutively refreshed every 2-3 days.  
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3.8.2 Expansion of antigen-specific T cells 
Protocol 1 
PBMCs were thawed and incubated in Iscoves medium (PAA) supplied with 
human AB serum (10%, PAA). Mononuclear cells from PB samples were 
cultured together with different peptides, IL-2 (50 IU/ml; R&D Systems, 
Wiesbaden, Germany) and IL-7 (10 ng/ml; R&D Systems) for 10 days for 
initial antigen-priming. During that period medium and leukines were refreshed 
every 2-3 days.  
Protocol 2 
PBMCs were thawed and incubated in Iscoves medium (PAA) supplied with 
human AB serum (10%, PAA). Mononuclear cells from PB samples were 
cultured together with different peptides, IL-4 (5 ng/ml; R&D Systems) and IL-
7 (10 ng/ml; R&D Systems) for 10 days for initial antigen-priming. During that 
period medium was refreshed every 2-3 days. The medim was inoculated with 
IL-2 (50 IU/ml) and IL-4 (5 ng/ml) on a two-day interval. 
Protocol 3 
PBMCs were thawed and stained with fluorochrome-conjugated antibodies to 
CD3 (FITC), CD8 (PE) and with fluorochrome-conjugated WT1128-134-
Tetramers (APC). CD3, CD8 and WT1128-134-Tetramer triple positives were 
sorted as single cells into 96 well plates, containing approx. 105 feeder-cells per 
well together with phytohemagglutinin (PHA) and 120 U/ml IL-2. Plates were 
incubated and medium was changed every 3-4 days. Following 10 – 14 days of 
incubation, growing clones were transferred into new 96 well plates together 
with feeder cells and further expanded. 
Protocol 4 
PBMCs were thawed and incubated in Iscoves medium (PAA) supplied with 
human AB serum (10%, PAA). Mononuclear cells from PB samples were 
primed with different peptides. On day 1 IL-7 (20 ng/ml) and IL-12 (0.5 ng/ml, 
R&D Systems) were added and the cells were incubated for 10 days. During 
that period medium was refreshed every 2-3 days and inoculated with IL-2 (30 
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IU/ml). In addition, the expanded cells were weekly restimulated with 
autologous irradiated and peptide-primed PBMCs. 
Protocol 5 
PBMCs were thawed and incubated in Iscoves medium (PAA) supplied with 
human AB serum (10%, PAA). Mononuclear cells from PB samples were 
primed with different peptides. On day 1 IL-7 (20 ng/ml), IL-10 (10 ng/ml, 
R&D Systems) and IL-12 (0.1 ng/ml) were added and the cells were incubated 
for 10 days. During that period medium was refreshed every 2-3 days and 
inoculated with IL-2 (30 IU/ml). In addition, the expanded cells were weekly 
restimulated with autologous irradiated and peptide-primed PBMCs. 
Protocol 6 
PBMCs were thawed and incubated in Iscoves medium (PAA) supplied with 
human AB serum (10%, PAA). Mononuclear cells from PB samples were 
primed with different peptides. On day 1 IL-6 (10 ng/ml, R&D Systems) and 
IL-12 (5 ng/ml) were added and the cells were incubated for 10 days. During 
that period medium was refreshed every 2-3 days and inoculated with IL-2 (30 
IU/ml). In addition, the expanded cells were weekly restimulated with 
autologous irradiated and peptide-primed PBMCs. 
Protocol 7 
PBMCs were thawed and incubated in Iscoves medium (PAA) supplied with 
human AB serum (10%, PAA). Mononuclear cells from PB samples were 
primed with different peptides. On day 1 IL-7 (20 ng/ml) and on day 5 IL-15 (5 
ng/ml, R&D Systems) were added and the cells were incubated for 10 days. 
During that period medium was refreshed every 2-3 days and inoculated with 
IL-2 (30 IU/ml). In addition, the expanded cells were weekly restimulated with 
autologous irradiated and peptide-primed PBMCs. 
Protocol 8 
PBMCs were thawed and incubated in Iscoves medium (PAA) supplied with 
human AB serum (10%, PAA). Mononuclear cells from PB samples were 
primed with different peptides. On day 1 IL-6 (10 ng/ml) and IL-12 (5 ng/ml) 
were added and the cells were incubated for 10 days. During that period 
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medium was refreshed every 2-3 days and inoculated with IL-2 (30 IU/ml). In 
addition, the expanded cells were weekly restimulated with autologous 
irradiated and peptide-primed PBMCs and inoculated with IL-7 (10ng/ml). 
3.9 Flow cytometric analysis 
3.9.1 T cell panel 
Following the thawing of cryopreserved samples and overnight resting, antigen-
specific T cells were analyzed by intracellular cytokine staining after a short time of 
incubation with WT1 candidate epitopes or irrelevant peptides as described 
previously [261]. In brief, PBMC (2 × 106) were incubated with 10 μg/ml of each 
peptide and xxx of Monensin. After 2 hours, 10 µg Brefeldin A (Sigma, 
Deisenhofen, Germany) were added, and after 16 additional hours, PBMCs were 
stained with fluorochrome-conjugated monoclonal antibodies against surface 
molecules. Afterwards, FACS Lysing Solution and FACS Permeabilization Solution 
(Becton Dickinson) were added, and intracellular molecules were stained identically. 
Data acquisition was done on a FACSCantoII cytometer and analyzed using FlowJo 
Software. A T cell response was considered positive if the frequency of CD3+CD8+ T 
cells producing cytokines in response to the candidate epitope was at least 2-fold 
higher compared to an irrelevant peptide, and if there was a minimum of 0.05% of 
cytokine+CD3+CD8+ T cells after the subtraction of the irrelevant peptide 
background response. 
Antibody Fluorochrome Amount [µl]  Antibody Fluorochrome Amount [µl] 
CD3 AmCyan 5  CD3 AmCyan 5 
TNFa PE-Cy7 0.5  TNFa PE-Cy7 0.5 
CD137 APC 20  Il-2 APC 1 
IFNy FITC 20  IFNy FITC 20 
PD1 PE 15  CD107a PE 20 
Il-2 Biotin+SAV –
PerCP 
0.5+0.5  CCR7 +GAM-Biotin+SAV 
-PerCP 
1+1+1 
ViVid PacificBlue  0.5  ViVid PacificBlue  0.5 
CD8 APC-H7 5  CD8 APC-H7 5 
Table 9: Index of the two different staining panels used to identify possible T cell defects. Left 
panel: Focus on the exhaustion (PD-1) and/or impaired activation (CD137) of T cells. Right panel: 
Focus on impaired cytotoxic activity (CD107a) and phenotype (CCR7) of T cells. 
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3.9.2 Treg-panel 
Following thawing of cryopreserved samples and overnight resting, regulatory T 
cells were detected by FACS after an overnight-incubation with Staphylococcus 
aureus enterotoxin B (SEB) for CD137-detection.  
PBMCs were then stained with fluorochrome-conjugated monoclonal antibodies 
against surface molecules as listed in Table 10 and analyzed using a FACSCantoII 
cytometer and FlowJo Software. 
Antibody Fluorochrome Amount [µl] 
CD4 PE-Cy7 3 
CD8 APC-H7 5 
CD137 APC 20 
CD127 FITC 20 
CD25 PE 10 
CD3 PerCP 10 
ViVid PacificBlue  0.5 
Table 10: Index of the antibodies used to detect regulatory T cells in PBMCs. 
3.9.3 MDSC-panel 
Following thawing of cryopreserved samples, MDSC were detected by FACS. 
PBMCs were stained with fluorochrome-conjugated monoclonal antibodies against 
surface molecules according to Table 11 and analyzed using a FACSCantoII 
cytometer and FlowJo Software. 
Antibody Fluorochrome Amount [µl] 
Trash : CD19 FITC 10 
CD56 10 
CD3 10 
CD11b PE-Cy7 1 
HLA-DR PE 20 
ViVid PacificBlue 0.5 
CD14 APC 3 
Table 11: Index of the antibodies used to detect myeloid-derived suppressor cells in PBMCs. 
3.9.4 Leukemic blast: immune regulatory-panel 
Following thawing of cryopreserved samples and overnight resting, FACS Lysing 
Solution and FACS Permeabilization Solution were added, and extra- and 
intracellular molecules were stained as listed in Table 12 and analyzed using a 
FACSCantoII cytometer and FlowJo Software. 
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Antibody Fluorochrome Amount [µl] 
CD3 AmCyan 5 
CD33/34 PE-Cy7 4 
CD274 APC 10 
HO-1 FITC 0.5 
INDO PE 8 
CD14 PerCP 5 
ViVid PacificBlue  0.5 
PI-9 +GAM-Biotin + SAV750 8+0.5+0.5 
Table 12: Index of the antibodies used to detect immune modulators on leukemic blasts. 
3.9.5 Leukemic blast: WT1/HLA-A2-panel 
Following thawing of cryopreserved samples and overnight resting, cells were fixed 
with 1% formaldehyde and permeabilized with 0.2% TritonX for 5 min on ice. For 
intranuclear staining, murine anti-hWT1 antibody was allowed to bind for 20 min. 
After consecutive incubation with goat-anti-mouse-PE antibody, additional extra- 
and intracellular molecules were stained time-delayed, due to their murine nature, as 
listed in Table 13 and analyzed using a FACSCantoII cytometer and FlowJo 
Software. 
Antibody Fluorochrome Amount [µl] 
CD80/86  FITC 15 
HLA-A2  Alexa647 8 
WT1  PE 3+GAM-PE ,5+ 
ViVid  PB 0.5 
Trash:  CD3 PerCP  10 
CD14 PerCP  10 
Table 13: Index of the antibodies used to determine WT1- and HLA-A2- expression on leukemic 
blasts. 
3.10 Expression patterns of immune modulators by leukemic 
blasts  
3.10.1 Control groups 
To assess comparative data on the expression levels of the selected immune 
modulators, blood samples of healthy controls (n=5), of patients with different solid 
tumor entities (n=14) and of AML patients not included in our therapeutic setting 
(n=5) served as control-groups (Table 14). 
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Group Patient Sex Born Diagnosis 
Healthy M15 F 1977  
M17 F 1967  
M18 F n. a.  
M19 F 1979  
M20 M 1979  
AML P40 M 1929 AML 
P41 M 1928 AML 
P51 F 1927 AML 
P69 F 1966 AML 
P88 M 1935 AML 
Entities E1 M 1961 B-NHL 
E2 M 1940 Bronchial carcinoma 
E3 F 1935 Bronchial carcinoma 
E4 F 1940 Bronchial carcinoma 
E5 M 1942 Colorectal carcinoma 
E6 F 1937 Colorectal carcinoma 
E7 F 1933 Endometric / cervical carcinoma 
E8 M 1944 Hypopharyngal carcinoma 
E9 M 1949 Head/neck cancer 
E10 M 1947 Liposarcoma 
E11 F 1946 Oral cavity carcinoma 
E12 M 1928 RCC 
E13 M 1929 RCC 
E14 F 1945 Pankreatic carcinoma 
Table 14: Characteristics of the control groups for qRT-PCR. 
 
3.10.2 Messenger-RNA (mRNA) isolation 
PBMCs were centrifuged at 1600 × g for 10 min and the cell pellet was resuspended 
in 1 ml of guanidium thiocyanate (GTC) buffer and stored at −80°C. Total RNA was 
isolated from PBMCs with the RNeasy® Mini Kit including RNase-Free DNase Set 
(both: Quiagen, Hilden, Nordrhein-Westfalen, Germany) according to the 
manufacturer’s recommendations. Briefly, cells, stored at -20°C in GTC-buffer, were 
carefully thawed and applied on a QIAshredder-column and centrifuged. The filtrate 
was mixed (1:1) with 70% ethanol and transferred to an RNeasy-column. Intercepted 
by several centrifugation- and washing-steps, the sample was incubated with DNase 
and finally eluted in 53 µl of PCR-grade, RNase-free water. Determination of the 
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RNA-yield was performed on a NanoDrop® ND-1000 spectrophotometer (Thermo 
Fisher Scientific, Wilmington, Delaware, USA). RNA was stored at -80°C. 
3.10.3 Complementary-DNA (cDNA) synthesis 
Complementary-DNA-synthesis was performed with the Omniscript® RT Kit 
(Quiagen) according to the manufacturer’s recommendations. Briefly, a maximum of 
2 μg of RNA were diluted in 15 μl of RNase-free water, incubated for 5 min at 65°C, 
and placed on ice. A 7.5-μl mixture containing 2 μl of oligo-p(dT)15 primer (0.8 
μg/μl), 2 μl of dNTPs (5 mM), 0.5 μl of RNase-inhibitor (40 units/μl), 1 μl of 
Omniscript® Reverse Transcriptase (4.5 units/μl) and 2 μl of reverse transcriptase 
buffer (×10) was prepared and added to the diluted RNA. After incubation at 37°C 
for 1 h, Omniscript® Reverse Transcriptase was inactivated for 5 min at 95°C, and 
cDNA was stored at −20°C. All reverse transcriptase reagents, except oligo-p(dT)15 
primers and RNase-inhibitor (Roche Diagnostics, Mannheim, Germany), were 
purchased from Qiagen. 
3.10.4 Quantitative real-time PCR 
PCRs were performed on a LightCycler (Roche Diagnostics). Each cDNA (2 μl) was 
diluted to a volume of 20 μl of PCR mix (LightCycler Faststart DNA Master 
Hybridization Probes; Roche Diagnostics), containing 0.5 pmol of primer and 0.2 
pmol of probe and a final MgCl2 concentration as listed in Table 4.  
 PD-L1 TGF PI-9 HO-1 IL10 CXCR4 INDO 
Annealing 57°C 57°C 58°C 58°C 60°C 56°c 60°C 
Elongation 12 s 10s 10 s 10 s 10s 7s 12 s 
[MgCl2] 2,5 mM 5 mM 3 mM 3 mM 4 mM 4mM 3 mM 
Table 15: Optimized qRT-PCR conditions for each of the immune modulators. Annealing 
temperatures, elongation time and MgCl2-concentrations were determined by preliminary 
experiments. 
Primers were purchased from Metabion (Martinsried, Germany) and fluorophore 
probes from TIB Molbiol (Berlin, Germany) and Metabion. For amplification, an 
initial denaturation step at 95°C for 10 min was used. For 50 subsequent cycles, the 
conditions were denaturation for 10 s at 95°C, annealing for 12 s at a target-specific 
temperature, followed by a target-specific elongation at 72°C (specific values 
provided in Table 15). Final extension was performed at 72°C for 2 min. The 
expected size of the PCR product was confirmed by agarose gel electrophoresis.All 
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samples were analyzed in duplicate on the expression of the control gene 
porphobilinogen deaminase (PBGD) and the target genes. The average value of both 
duplicates was used as a quantitative value. If only one of the duplicates gave a 
positive result, the positive result was taken.  
3.10.5 Primers 
Target Type Sequence 
PD-L1 Forward 5’-ACT TAA AAG GCC CAA GC-3’ 
Reverse  5’-CCG TTC CAA CAC TGA G-3’ 
LC 5’-LCRed640-GGA GTC AAA CAG GGA GCC T-Pho-3’ 
FL 5’-AGC AGA GGA GGA GAA TGA AGA AAG-Fluo-3’ 
TGF-β Forward 5’-CCC ACA ACG AAA TCT ATG AC-3’ 
Reverse  5’-GCT AAG GCG AAA GCC C-3’ 
LC 5’-LC Red640-AGA GTG GTT ATC TTT TGA TGT CAC CG-Pho-3’ 
FL 5’-GGC ACC CAG CGA CTC G-Fluo-3’ 
PI-9 Forward 5’-GTG CTT CGG CAT TTG G-3’ 
Reverse  5’-CCC TTT ATG GCG ATG AG-3’ 
LC 5’-LC Red640-GTG TCT GTC CAA GTT CGT GC-Pho-3’ 
FL 5’-GCA ATG TCA GCG GAG AGA GAC-Fluo-3’ 
HO-1 Forward 5’-CCC AAC GAA AAG CAC AT-3’ 
Reverse  5’-CAG TGC CGT TAA ACA-3’ 
LC 5’-LC Red640-GTC AGC CCT GCC CTT CAG-Pho-3’ 
FL 5’-AAA CTT CAG AGG GGG CGA AG-Fluo-3’ 
CXCR4 Forward 5’-GTG ACC GCT TCT ACC C-3’ 
Reverse  5’-AGT CGA TGC TGA TCC C-3’ 
LC 5’-LC Red640-ATC CTG GCT TTC TTC GCC T-Pho-3’ 
FL 5’-CCC TCA AGA CCA CAG TCA TCC-Fluo-3’ 
IL-10 Forward 5’-CCT TCC AGT GTC TCG G-3’ 
Reverse  5’-TGG AGT ACA GGG GCA T-3’ 
LC 5’-LC Red640-AGG TCA GGA GTT CCT AAC CAG-Pho-3’ 
FL 5’-AGG CGG GTG GAT CAC T-Fluo-3’ 
INDO Forward 5’-ACG ATC ATG TGA ACC CA-3’ 
Reverse  5’-AGC TCC TCA GGG AGA C-3’ 
LC 5’-LC Red640-CAG TCC GTG AGT TTG TCC TT-Pho-3’ 
FL 5’-CTT CCT GTG CTC ATT AGA GTC AAA TCC-Fluo-3’ 
PBGD Forward 5’-TGC AGG CTA CCA TCC ATG TCC CTG C-3’ 
Reverse  5’-AGC TGC CGT GCA ACA TCC AGG ATG  T-3’ 
LC 5’-LC Red640-TGT GGG TCA TCC TCA GGG CCA TCT TC-Pho-3’ 
FL 5’-CGT GGA ATG TTA CGA GCA GTG ATG CCT ACC-Fluo-3’ 
Table 16: Index of primers utilized for qRT-PCR. LC = LC Red 640; FL = Fluorescein; Pho = 
Phosphate 
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3.10.6 Plasmid Controls, Standard Curve. 
PCR products generated from cDNAs were cloned into the vector pCR2.1-
topoisomerase (Invitrogen, Karlsruhe, Germany). Recombinant vectors, linearized 
with EcoRV, were serially diluted in water containing 0.4 μg/μl polyadenylic acid 
(Pharmacia Biotech, Freiburg, Germany). A standard curve with three dilutions of 
the respective plasmid in duplicates (1, 0.1, and 0.001 pg/μl) was included in each 
PCR run (Figure 15).  
 
Figure 15: Standard curve and linear regression of the INDO-control. Indo-plasmid was 
amplified by PCR at different start-dilutions (1, 0.1, and 0.001 pg/μl). CV-values were plotted versus 
logConcentration and fitted by a trendline.  
 
3.10.7 Precautions 
To reduce risk of contamination, RNA extraction, cDNA synthesis, thermocycling, 
and post-PCR steps were performed in separate laboratories. PCR mixtures were set 
up in a template tamer (Oncor Appligene, Heidelberg, Germany). All reagents for 
cDNA synthesis were prepared with RNase-free water. For all RT-PCR steps, 
negative controls were performed as outlined in the EORTC recommendations[262], 
including a reverse transcriptase-negative sample control for every sample and water 
control for every PCR run.  
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3.10.8 Data Analysis 
With the LightCycler software (version 3), crossing points were assessed and plotted 
versus the concentrations of the standards. The relative sample amount was 
expressed as ratio marker (target gene)[pg/μl]/(PBGD)[pg/μl]. The crossing points 
(beginning of the PCR exponential phase) for each reaction were determined by the 
Second Derivative Maximum algorithm, and sample concentration was calculated 
using the plasmid standard curve.  
3.11 Cytotoxicity Assays 
The methodical background of the cytotoxicity assays is explained in detail in 
section 4.7. 
3.12 Stochastic evaluation 
Stochastic evaluation concerning the correlation of the clinical response and the 
induction of WT1-specific IgM-antibodies was performed by using the standard t-
test. Differences between healthy donors and AML patients were evaluated using the 
Mann-Whitney test, whereas variations between pre- and postvaccine samples were 
analyzed using the Wilcoxon matched pairs test. The statistical evaluation of the 
Kaplan-Meier curves, concerning PFS in terms of PD-1 expression and CCR7-
variances were performed using the logrank test. Further statistical analyses for other 
functional assays were performed using the Mann-Whitney test.  
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4 Results 
4.1 Humoral immunity against WT1 and KLH in AML patients 
vaccinated with WT-1-peptide plus GM-CSF and KLH  
It has been shown that immunoglobulins specific to WT1 are present in patients with 
hematologic malignancies, comprising AML [124]. In the setting of a phase II 
vaccination we examined if WT-specific antibodies can be induced and/or boosted 
by the consecutive vaccination with an HLA-A201-restricted WT1126–134 epitope in 
combination with KLH and hGM-CSF used as adjuvants. In 14 patients serum 
samples at baseline and during the course of vaccination were collected and screened 
for specific immunoglobulins. 
4.1.1 Vaccination of leukemia patients with a MHC class I peptide of 
WT1 with unspecific T helper stimulation is able to induce WT1-
specific IgM responses but fails to induce IgG responses  
p = 0,05
A B
 
Figure 16: WT1-specific antibody profiles in PB and correlation of IgM induction and clinical 
outcome. A) Immunoglobulin-distribution during vaccination course. Values ≥ 700 for IgM and 
values ≥ 1000 for IgG were considered positive (mean of healthy donors + 2 fold SD). Each value 
shown represents an average of at least 2 experiments. B Correlation of IgM-titer and clinical outcome 
of patients. Mean values are indicated as grey bars. CR =complete remission, PD = progressive 
disease, SD = stable disease. 
We examined if consecutive vaccination with an HLA-A2-restricted WT1-peptide 
would have an impact on the humoral immune response against the WT1 protein. 
The analyses of WT1-antibodies were performed in cooperation with Olga A. 
Elisseeva in Osaka, Japan.  
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Humoral responses against WT1 were analysed at baseline in 14 patients and during 
the course of vaccination in week 10 (n=8), in week 18 (n=7) and week 26 or 30 
(n=6) by dot-blot analyses. At baseline IgM responses, defined as an IgM-titer ≥ 900 
units were detected in 2 out of 14 patients available for WT1 antibody responses 
(Figure 16 A). An induction of anti-WT1-IgM antibodies was detected in 2 out of 7 
patients at week 18 and in 6 out of 6 patients at weeks 26 or 30 during the time 
course, but never earlier. This effect correlated with improved clinical outcome 
according to progression-free survival (PFS) (Figure 16). 
Spontaneous IgG responses at baseline were recorded in 3 out of 14 patients (Figure 
16 B). In contrast to the IgM responses, no WT1-specific IgG antibody responses 
could be induced or enhanced by vaccination. The inability of induction of WT1-
specific IgG antibodies might be related to the lack of specific T-helper cell 
stimulation. This hypothesis is underlined by the inability to detect functional WT1-
specific CD4 T cells by intracellular cytokine staining (data not shown). 
4.1.2 Vaccination of leukemia patients is able to induce both, KLH-
specific IgM and IgG responses 
As an antigen-independent CD4-helper cell stimulus Keyhole Limpet Hemocyanin 
was used as adjuvant in the vaccine. 
Patient IgM IgG 
 pre W10 W18 W26/30 pre W10 W18 W26/30 
13 0.45 0.66   0.54    
14 0.58 0.74   0.90 0.99   
15 0.64 0.44   1,63 0.98   
16 0.43  0.42  0.61  0.95  
17 0.52   0.67 0.59   1,01 
18 0.48 0.46 0.49  0.37 0.93 0.82  
19 0.50 0.44   0.98 1,04   
20 0.58 3,11   0.73 0.97   
21 0.71  1,49  0.77  0.84  
22 0.52 0.71   0.75 0.68   
23 0.75 1,06  0.45 0.66 0.65  0.72 
24 1,13 0.66 0.63 0.55 0.74 1,03 1,07 0.90 
25 0.48 0.52 0.41 0.39 0.56 1,22 1,56 1,58 
26 0.52  0.52 0.59 0.51  0.99 1,13 
Table 17: KLH-specific antibody profiles in PB. Values ≥ 0.7 for IgM and values ≥ 0.8 for IgG 
were considered positive (mean of healthy donors + 2 fold SD) 
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Because of the “non-self”-status and to assess if the vaccine-induced humoral 
response against an entire protein differs from the humoral responses against a small 
class-I-peptide epitope, the humoral anti-KLH response was analyzed. At baseline 3 
out of 14 patients exhibited spontaneous KLH-specific IgM responses, defined as 
E550 ≥ 0.7 (Table 17). Following vaccination enhanced KLH IgM antibody responses 
were detected in 4 out of 10 patients in week 10 and additionally in 1 patient in week 
18. 
Spontaneous IgG responses to KLH were measured in 3 out of 14 patients at 
baseline. In week 10, 4 out of 9 patients showed an induction of KLH-specific IgG-
antibodies, whereas 4 out of 4 patients had enhanced KLH-specific IgG-antibodies in 
week 18 or 26.  
4.1.3 Consecutive vaccination of leukemia patients leads to the 
induction of neutralizing GM-CSF-specific IgM and IgG 
antibodies. 
In our setting, GM-CSF acts as a chemo-attractant for different kinds of immune 
cells, especially dendritic cells (see also Figure 4). To conclude the investigations on 
humoral immune responses we also performed experiments to determine if the 
administered hGM-CSF also leads to the induction of specific antibodies.  
 
Figure 17: Specific anti-GM-CSF antibodies in sera of patients at different time points during 
vaccine course. a) Assorted Western-Blots, revealing the presence of GM-CSF-specific IgG-
antibodies in sera of patients. PV = pre-vaccine; V = in vaccination; K = positive control. b) Positive 
sera (anti-IgA-IgG-IgM-antibody) were further classified into IgG and IgM isoformes. 10/26, week 
10/26 after first vaccination;*positive for IgG-subtype at week 46; ∏only positive for IgA-IgG-IgM-
subtype 
 
Western-Blot-analyses were performed in 14 patients at baseline as well as in week 
10 and weeks 26 or 30. Serum of a rhesus macaque, previously described to contain 
anti-hGM-CSF antibodies [260] was used as positive control (Figure 17 A). At 
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baseline none of the patients’ sera showed any Ig-reactivity against hGM-CSF. Anti-
GM-CSF-IgM-antibodies were observed in 2 patients in week 10; IgG-responses 
could be detected in a total of 10 out of 14 patients (Figure 17 B).  
 
 
Figure 18: Detection of neutralizing anti-GM-CSF-antibodies a) Mechanism of the MTT-Assay. 
MTT is reduced to formazan by viable cells, leading to a color change, detectable via spectrometry. b) 
Preliminary experiment to determine an adequate GM-CSF concentration. The blue box indicates a 
GM-CSF range with maximal ∆E/∆GM-CSF. c) Identification of neutralizing antibodies in sera of 
several patients.  The red line indicates the uninfluenced growth of TF-1 cells with 2,5 ng/ml GM-
CSF. The green line indicates the growth of TF-1 cells deprived of GM-CSF. Error-bars indicate the 
mean of a triplicate experiment. 
 
Interestingly, following anti-tumor vaccination, three patients developed 
accompanying dry cough without radiologic abnormalities, which theoretically could 
be attributed to pulmonary alveolar proteinosis (PAP), a medical condition 
characterized by accumulation of surfactant in alveoli, which might be related to 
anti-GM-CSF autoantibodies. 
To investigate the neutralizing potential of the GM-CSF-antibodies we performed a 
MTT-Assay (Roche)[263, 264], using TF-1 cells which proliferate dependently on GM-
CSF, IL-3 or erythropoietin. MTT is internalized in viable cells and is reduced via 
NADH+ to a stable salt, called Formazan. This chemical transformation is 
accompanied by a color switch (Figure 18a) which can be detected 
photospectrometrically. By incubating TF-1 cells under different GM-CSF 
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conditions (Figure 18b) we identified an adequate GM-CSF concentration of 2.5 
ng/ml below which a minimal ∆GM-CSF would result in a maximal ∆E.   
As displayed in Figure 18c, neutralizing activity of 30% of anti-GM-CSF sera could 
be demonstrated in patients 21, 23, 24 and 26 when using the monkey serum as 
reference value. Interestingly, in none of the patients in which dry cough occurred 
neutralizing anti-GM-CSF antibodies could be detected. 
4.2 Phenotypical and functional analyses of cellular immunity in 
AML patients vaccinated with WT1-peptide plus GM-CSF 
and KLH  
In the context of the phase I/II study with WT1-peptide-vaccination in AML patients 
we could previously demonstrate immunological and clinical responses but did not 
observe a correlation between T cell responses and outcome parameters in the initial 
analyses of WT1-specific tetramer staining and intracellular cytokine staining for 
TNF-α and IFN-γ [93]. Therefore more detailed immunological analyses were 
performed in a subgroup of patients. In detail, phenotypic charcterisation of CCR7 
expression, induction of PD1 and CD137, and the cytokine profile by analyzing the 
capacity to produce IFN-γ, TNF-α and IL-2 and to mobilize CD107a, in response to 
the WT1 vaccine peptide were evaluated directly ex vivo.  
In neither WT1 specific CD3+ CD8+ T cells nor in the whole CD3+ T cell population 
a significant correlation could be found between cytokine or cytotoxic response or 
the activation marker CD137 and clinical outcome. 
4.2.1 Differences in clinical outcome can be correlated to the T cell 
exhaustion marker PD-1 
When evaluating the PD-1 data, we observed, that increased PD-1 values at baseline 
could be associated to influence PFS (p=0.05). Patients with PD-1 values exceeding 
0.6% of CD3+CD8+ T cells (n=9; mean= 1.937%; median=0.88%; range 0.6% -
6.01%) at baseline exhibited a median PFS of 132 days (range= 49 -201 days) while 
patients with low PD-1 frequencies (n=7, mean= 0.25%; median= 0.16%; range 
0.058% -0.2%) exhibited a significant longer PFS of 149 days (range= 57 -1682(+) 
days) (Figure 19 A). 
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Figure 19: Correlation of PD-1-levels and progression-free survival (PFS). A) A shorter PFS can 
significantly be attributed (p=0.05) to the subgroup of patients with high PD-1 expression. B) Scatter-
Plot of WT1-mRNA ratio distribution in both subgroups.  High values of PD-1 expression are 
correlated to increased WT1-mRNA level. 
Another trend, sustaining the reduced vaccine efficacy elicited by PD-1 can be seen 
when comparing the same groups in relevance to the differences in WT1-mRNA-
levels at baseline and at week 10 of vaccination therapy as calculated on 
(
0
10
WT1
WT1
1WTratio
W
W ). The patient subset exhibiting low quantities of PD-1 
exhibited an average reduction of the WT1-mRNA level (range = 0.016 – 1; mean = 
0.514; median = 0.62), while the patient subset with elevated PD-1 levels displayed 
an average increase in WT1-mRNA expression (range = 0.025 – 10; mean = 2.681; 
median = 0.95, p=0.05) (Figure 19 B).  
 
4.2.2 Variations of CCR7+-T cell frequencies are associated with 
clinical outcome  
To examine in which T cell subset, if at all, potential functional defects would occur, 
the maturation and homing marker CCR7 was costained in our cytokine profile 
analyses (see 3.9.1). In 16 patients CCR7-expression on the whole T cell population 
was evaluated at baseline and in week 10. The analyses showed two behavioral 
subsets of our patients on terms of CCR7 alterations during treatment (Figure 20). In 
one group CCR7-expression levels increased during vaccination, while in the other 
group CCR7-expression levels decreased during treatment. Our data revealed that, an 
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increase of CCR7+ CD8+ T cells in patients is significantly assoiciated with favorable 
clinical course.  
 
Figure 20: Determination of CCR7-frequencies. a) Gating strategy to determine CCR7-distribution: 
I.: lymphocyte gate; II.: singlet gate; III.: live/dead discrimination; IV: CD3+ gate; V.: CD3+CD8+ 
gate. b) Exemplary CCR7 distribution of one patient in week 0 (W0) and in week 10 (W10), showing 
CCR7-frequency shifting in both, the CD3+ CD8+ - and the total CD3+-population during time course. 
Patients with an increase of CCR7+ CD8+ T cell frequencies (46.4% week 0 to 67.4% 
week 10) during vaccination had a significantly (p<0.05) longer PFS (median= 383 
days, range 128-1682(+) days, n= 8) than patients with a decrease of CCR7+ CD8+ T 
cells (33.1% week 0 to 26.6% week 10) and a shorter PFS (median = 142 days, range 
57-201 days, n=8) (Figure 21). 
 
Figure 21: Kaplan-Maier-Plot showing differential progression-free survival of patient subsets. 
Patients with increase in memory cell frequencies exhibit significantly longer PFS than patients with 
reduced memory cell frequencies.  * = p ≤ 0.05 
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Evaluation of both subgroups on CCR7 surface expression did not reveal 
significantly different expression patterns of CCR7 at baseline (p ≥ 0.05), but 
diverged significantly during vaccination (p < 0.01) in and between the subgroups 
(Figure 22 A). We also monitored the relation between the differential CCR7 surface 
expression during therapy and the matching WT1-mRNA ratio (Figure 22 B). 
As seen in the corresponding graph, patients in whom CCR7-frequencies increase 
during vaccination exhibit a reduction of WT1-mRNA-levels in median as 
extrapolated by reduced WT1-expression levels in week 10 as compared to baseline. 
Nevertheless, this effect can not be scientifically determined, as statistics don’t 
deliver confidence > 95% and therefore remains interpretative. 
 
Figure 22: Correlation of CCR7-alteration and progression-free survival and WT1-mRNA 
expression. A) Differences in CCR7 surface expression display during vaccination. At baseline (week 
0, W0) both subgroups don’t exhibit significant differences in CCR7+ T cell frequencies, while the 
alterations in CCR7+ T cell frequencies in week 10 (W10) significantly differ in and between the 
subgroups. * = p ≤ 0.05; ** = p ≤ 0.01; ns = not significant. B) Scatter-Plot of WT1-mRNA ratio 
distribution in both subgroups. Increase of memory cells seems to be associated to reduction of WT1 
mRNA during vaccination.  
 
4.2.3 Clinical outcome is strongly associated to the interference of PD-1 
and CCR7 with T cell function, but both factors act 
independently. 
Since we could observe similar patterns concerning PD-1 and CCR7 expression in in 
relation to PFS, we plotted the patients with increased PD-1 levels as well as a 
decrease in CCR7 expression versus those in which one of these features was present 
and versus those who did not experience PD-1 induction and expressed CCR7 in 
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high amounts (Figure 23). We could observe a significant difference in PFS-values 
of the group with none of the detrimental markers (group A) to those which exhibited 
only one these markers (group B), as well as to those patients exhibiting both traits 
(group C). Overall PFS-values ranged from 49 to 1200 days (median = 143 days; 
mean = 312.5 days; n = 16). Group A exhibited a PFS range from 128 to 1200 days 
(median = 978 days; mean = 763.4 days; n=5) and was significantly elevated (p=** 
in both cases) compared to group B (PFS range from 49 to 149 days; median = 143 
days; mean = 126.8 days; n = 6) and group C (PFS range from 57 to 201 days; 
median = 101 days; mean = 112 days; n = 5).  
Therefore, in terms of PFS, it seems that the acquisition of one detrimental trait is 
sufficient to impair functional anti-tumor immunity and that T cell exhaustion and 
impaired homing capacity act independently. 
 
Figure 23: Effects of simultaneous acquisition of elevated PD-1 and decrease of CCR7-
expression on PFS and WT1-mRNA expression.  Left: simultaneous acquisition of high PD-1 
levels as well as a decrease in CCR7-frequencies has no significant impact on PFS compared to the 
acquisition of a single characteristic. Right: in contrast to PFS, the declination of WT1-mRNA values 
seems to follow a sequential trend in patients, exhibiting both, only one or none of these attributes.* = 
p ≤ 0.05; ** = p ≤ 0.01; ns = not significant.  
 
We also compared the same groups in order to determine potential associations of 
PD-1 and/or CCR7 to changes of WT1-mRNA during vaccination therapy (Figure 
23). Though not significant, we observed buoyancy to WT1 increase with 
accumulation of these receptors. Group A exhibited a lower WT1-mRNA ratio range 
from 0.016 to 1 (median = 0.18; mean = 0.376; n = 5) compared to group B (range 
from 0.22 to 4.7; median = 0.83; mean = 1.36 days; n = 6; p = 0.11) or group C 
(range from 0.025 to 10; median = 0.9; mean = 3.1; n = 5; p = 0.09).  
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4.2.4 Differentiation states of WT1-specific T cells at baseline and 
during therapy are not mirrored in clinical outcome. 
To further investigate if the differentiation status of WT1-specific T cells would be 
associated with vaccine efficacy, detailed phenotypic analyses were performed in 12 
patients (Figure 24). Presence of a WT1-specific T cell  at baseline were considered 
positive when they exceeded 0.3% of total CD3+CD8+ T cells, representing the 
mean value +2 SD of a control group; c.f. Keilholz et al. [93]. At baseline, all patients, 
except patient 6 (1.15 %), did not exhibit WT1-specific tetramer + T cells (mean = 
0.2 %; range = 0.05% - 1.15%; Figure 24, column graphs). After 6 vaccinations, 8 
out 12 patients exhibited an at least two-fold increase of initial WT1-specific 
tetramer + T cells (patients 1, 2, 10, 11, 18, 22, 25 and 26; mean = 0.51%; range = 
0.14% - 1.09%), including 5 patients with significantly elevated levels when 
compared to the threshold value (patients 1, 2, 11, 22, and 25; mean = 0.66%; range 
= 0.041% - 1.09%).  
 
In parallel to the flow-cytometric assessment of WT1-specific tetramer responses, the 
CCR7 and CD45 expression on the WT 1-tetramer-positive T cells was evaluated in 
the same experiment to allow discrimination of 4 main T cell subpopulations, naïve, 
central memory, effector memory and effector T cells (Figure 24, pie charts).  
Phenotypic distribution of the different T cell subsets proved to be heterogeneous 
among the individual patients. At baseline, mean values of total CD3+CD8+ WT1-
specific T cells appointed 24.7% to the Tnaïve subset (range = 2% – 46%), 11.7% to 
the Tcm subset (range = 0% – 41%), 12.1% to the Tem subset (range = 0% – 33%) and 
51.3% to the Teff  subset (range = 5% – 86%), respectively. After 6 vaccinations, the 
total CD3+CD8+ WT1-specific T cells comprised mean values of 21.25% of the Tnaïve 
subset (range = 3% – 54%), 9.95% of the Tcm subset (range = 0% – 54%), 18.2% of 
the Tem subset (range = 1% – 84%) and 50.55% of the Teff subset (range = 12% – 
93%), respectively. However, no correlation could be found between variances in the 
phenotypic composition and clinical outcome in terms of PFS (data not shown). 
Interestingly, patient 6, with initially elevated frequencies of WT1-specific T cells, 
exhibited an almost constant level of WT1-specific T cells after 6 vaccinations 
accompagnied by an equally stable phenotypic constellation.  
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Patient 1 Patient 2 Patient 6 Patient 10 
    
Patient 11 Patient 18 Patient 19 Patient 22 
    
Patient 23 Patient 24 Patient 25 Patient 26 
    
Figure 24: Presence and phenotypic composition of WT1-specific T cells in PB of selected 
patients. WT1 specific T cells were identified at baseline and after the 6th vaccination by WT1 
specific tetramer staining of the CD3+CD8+ lymphocyte fraction (column graphs) for each patient. In 
parallel, the phenotypic composition of this specifc subset was assessed by CD45RA/CCR7-staining, 
identifying naïve (Tn), central memory (Tcm), effector memory (Tem) and effector (Teff) T cells (pie 
charts). 
Similar heterogenic variances were observed in the total lymphocyte fraction. The 
phenotypic distribution of the different T cell subsets at baseline showed mean 
values of total lymphocytes comprising 34.93% of the Tnaïve subset (range = 1.5% – 
57%), 16.75% of the Tcm subset (range = 0.5% – 54%), 10.56% of the Tem subset 
(range = 2.5% – 15%) and 37.69% of the Teff subset (range = 1.5% – 88%), 
respectively. After 6 vaccinations, the total lymphocytes accounted for mean values 
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of 30.19% of the Tnaïve subset (range = 5% – 70%), 13.25% of the Tcm subset (range 
= 0.5% – 28%), 11.62% of the Tem subset (range = 2% – 20%) and 44.81% of the Teff 
subset (range = 12% – 86%), respectively (individual data not shown, but 
summarized in Figure 25 B). 
 
Figure 25: Proportions of different T cell subsets among WT1-specific T cells and total 
lymphocytes at baseline and after the 6th vaccination. A Percentages of the T cell subsets in the 
WT1-specific CD3+CD8+ T cell fraction acoording to CCR7/CD45RA-staining. B Percentages of the 
T cell subsets in the total lymphocyte fraction acoording to CCR7/CD45RA-staining. Mean values are 
indicated as grey bars. 
 
Despite no general significant alteration in the proportions of the T cell subsets could 
be observed among the patients, significant intra-individual shifts occur in both, the 
WT1-specific CD3+CD8+- as well as in the total lymphocyte population (Figure 25). 
Nevertheless, the initial heterogeneity of the individual patients concerning their 
phenotypic composition does not allow any assumption about vaccine associated 
effects. 
 
Due to their clinical performance (PFS ≥ 514 days; c.f. Table 6), additional long-term 
analyses could be performed in 4 of the 12 selected patients (patients 1, 2, 22 and 24, 
respectively).  
Despite the initial increase in WT1-specific T-cells, patient 1 (PFS = 514 days) 
exhibited an oscillating pattern concerning the frequencies of WT1-specific T-cells. 
A boosting of WT1-specific T-cells after the 6th vaccination was followed by a 
consecutive reduction of WT1-specific T-cells at the next reading ? point (Figure 
26). Interstingly this effect was accompagnied by a pattern in the phenotypic 
composition. Apparently, with already high levels of TEFF cells at baseline, the initial 
boost of WT1-specific T-cells leads to the predominace of TEFF cells and an almost 
complete depletion of WT1-specific- TEM cells in this patient after 6 vaccinations. As 
TEFF cells exhibit a limited lifespan, the low frequencies of WT1-specific T-cells 
after 10 vaccinations may be explained by the declination of the primary vaccine-
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induced immune response. A similar picture could be observed concerning the 
timepoints after 15 and 20 vaccinations, respectively. After the 15th vaccination, the 
WT1-specific T-cells re-increased to a value comparable to the initial boost after 6 
vaccinations, but declined again at the reading point after the 20th administration. 
Simultaneously, the phenotypic composition equally mirrored the composition 
observed at the initial boost with a predominace of TEFF-cells and a depletion of TEM-
cells.  
 
Patient 1 Patient 2 
  
Patient 22 Patient 24 
  
Figure 26: Presence and phenotypic composition of WT1-specific T cells in PB of long-
performing patients. Complementing the initial analyses, WT1 specific T cells were additionally 
identified after the 10th, 15th and 20thvaccination, if material was available (column graphs). In 
parallel, the phenotypic composition of these subsets was assessed by CD45RA/CCR7-staining as 
performed before (pie charts). 
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While patient 2 (PFS = 978 days) exhibited similar features concerning the 
oscillation of WT1-specific T cells during vaccination, no associated pattern could be 
found when exmaning the phenotypic composition of the WT1-specific T cells.  
As already presented in Figure 24, Patient 22 (PFS > 1682 days) exhibited initially 
low WT1-tetramer-frequencies. After the 6th vaccination WT1-specific T-cells 
significantly increased and constituted 1.09% of total CD3+CD8+- T cells. 
Throughout the treatment phase WT1-frequencies declined to 0.54% after the 10th 
vaccination but recovered to 0.77% after the 15th vaccination (Figure 26) and 
remained stable since (data not shown). This development was accompied by a high 
presence WT1-specific effector-memory T cells after the 6th administration, probably 
due to an occurring vaccine-primed anti-tumor reaction. As the amount of WT1-
specific T cells levels off at a stable frequency, the phenotypic composition also 
seems to attain a new equilibrium with an increased fraction of effector T cells, 
indicating an ongoing active immune response against leukemic blasts. Nevertheless, 
the initially elevated TEM equally remains stable, indicating the establishment of an 
immunologic memory and probably serving as a source for the permanent reservoir 
of tumor-directed effector T-cells.  
Despite the unexpected long clinical and effective molecular response of patient 24, 
the immunologic response remained weak in relation to the beneficial clinical course 
in terms of PFS (> 1668 days). From vaccination initiation the patient exhibited only 
weak frequencies of WT1-specific T cells.  
4.3 Influence of immune regulatory cells 
4.3.1 Regulatory T cell frequencies in AML patients are significantly 
elevated, but time-dependent variations in Treg-frequencies can 
not be correlated to prognosis 
As mentioned above, several groups have described an influence of regulatory T 
cells on proper T cell functions in the context of anti-tumor immunity. For this 
reason we screened our patients for the presence of peripheral Tregs (Figure 27).  
Regulatory T cells in peripheral blood were assessed by flow cytometry and defined 
as CD25+CD127low cells (Figure 27 A). Although this definition predominantly 
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applies to CD4+ T cells, we expanded this definition to equally screen for potential 
regulators in the CD8+ and the total CD3+ fractions.  
In general, Treg-frequencies remain stable over time in the vaccinated AML patients. 
There are some distinct outliers, in which Treg frequencies vary significantly, but the 
low number of these special cases does not allow any assumptions of specific 
vaccine-associated effects. AML-patients exhibit significantly elevated frequencies 
compared to those of healthy volunteers (Figure 27 B). CD25+CD127low – 
frequencies in the CD4+ fraction of AML patients oscillate around 6% of the total 
CD3+-fraction  (W0: mean = 6.27%; median = 5.33%; range: 0.33% - 14.67%; W10 : 
mean = 6.01%; median = 5.47%; range: 0.39% - 15.74%;  n= 16), while healthy 
individuals exhibit lower levels of Treg (mean = 2.14%; median = 2.62%; n = 5) in a 
condensed range (0.72% - 2.98%).  
 
Figure 27: Assessment of Treg –frequencies. A) Gating strategy to identify regulatory T cells: I.: 
lymphocyte gate; II.: live/dead discrimination; III: CD3+ gate; IV.: CD4+ and CD8+ gates; V.: 
CD25+CD127low -subset b) Distribution of regulatory T cells in peripheral blood of controls and AML 
patients during vaccination. Scatter-plots show CD25+CD127low frequencies in terms of [%CD3+]. 
Plots were generated for CD4+ and CD8+ fractions of CD3+ lymphocytes, as well for the cumulative 
values (designated CD3+) of both subsets. Mean values are displayed as grey bars. * = p ≤ 0.05; ** = 
p ≤ 0.01; ns = not significant.  
 
The same effect holds true for CD8+CD25+CD127low Tregs: significant differences of 
AML patients in comparison to healthy controls, but also no alterations during 
vaccination course. However, it is noteworthy, that we are able to describe elevated 
levels of CD8+CD25+CD127low cells in our AML patients. To our knowledge, this 
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phenotype has not been described previously in AML. Healthy controls only exhibit 
very low numbers of the specified phenotype (mean = 0.20%; median = 0.16%; 
range: 0.12% - 0.33%). In contrast, AML patients show distinct populations of 
CD8+CD25+CD127low Tregs (W0: mean = 1.9%; median = 1.19%; range: 0.019% - 
7.12%; W10: mean = 2.85%; median = 1.28%; range: 0.04% - 17.76%).  
4.3.2 Myeloid derived suppressor cells are elevated in AML patients 
vaccinated with WT1, but have no impact on clinical outcome   
In the context of cellular immune suppressive factors we also screened our patients 
for the presence of peripheral myeloid derived suppressor cells at baseline and in 
week 10. MDSC were characterized as CD11+CD14+HLA-DR-/low cells that did not 
express lymphoid markers (CD3, CD19 and CD56). 
We could observe a significantly elevated amount of MDSC in our patients at 
baseline (mean = 1.78%, range = 0.005% - 10.42%; median = 0.66% n=16) 
compared to healthy donors (mean = 0.36%, range = 0.027% - 1.68%; median = 
0.28% n=19) with a confidence interval > than 95% (Figure 28). During vaccination, 
a trend aroused in regards of a drop of the mean frequencies of MDSC in the AML 
patients (W10: mean = 0.91%, range = 0.012% - 5.36%; median = 0.49%; p=0.08; 
n=16), but could not be proven statistically (p = 0.08). Despite the potential reduction 
of MDSC in peripheral blood of AML-patients, the median level remained 
statistically elevated compared to the control group.  
 
 
Figure 28: Evaluation of MDSC –frequencies in PB. A) Gating strategy to identify MDSC: I.: 
lymphocyte gate; II.: live/dead discrimination; III.: Trash- CD14+ gate; IV.: CD11+ HLA-DR-/low gate; 
B) Distribution of myeloid derived suppressor cells in peripheral blood of AML patients during 
vaccination and controls. * = p ≤ 0.05. 
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Additionally, MDSC frequences were analysed at timepoint of relapse in 15 patients. 
In 10 patients MDSC frequencies were analysed in BM and in 5 patients PB-samples  
were available for MDSC-frequency 
assessment. In comparison to the same 
compartment at week 0, baseline values 
were comparable to those of the 
preliminary, pure PB-screening (mean = 
1.28%, range = 0.008% - 7.6%; median = 
0.41% n=15). MDSC-frequencies were 
slightly elevated at time of relapse but did 
not significantly differ compared to 
baseline (mean = 1.464%, range = 0.027% 
- 4.74%; median = 0.93%; p=0.08; n=15) 
due to the two outliers at baseline (Figure 
29). 
 
Figure 29: Evaluation of MDSC-frequencies 
at relapse. Despite elevated levels of MDSCs at 
relapse, these frequencies do not significantly 
differ from those at baseline. * = p ≤ 0.05; ns = 
not significant. 
4.3.2.1 Tregs and MDSC are not linked in a common regulatory network 
in patients vaccinated with WT1 
As it has been described that MDSCs and Tregs may be interacting through a common 
regulatory network [231, 265], we also examined if the individual frequencies of both 
cell subsets would be related during vaccination. As seen in (Figure 30), no 
significant association could be found between the variances in Treg- and MDSC-
frequencies. 
 
 
Figure 30: Correlation of MDSC- 
and Treg- frequencies. Variances 
in Treg-frequencies during therapy 
were plotted against the 
corresponding variances in MDSC-
frequencies of the individual 
patients. In our specific context, 
MDSCs and Tregs do not seem to 
interact in a common regulatory 
network. 
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4.4 Expression of immune modulators on leukemic blasts 
Despite initial benefit in response to the vaccine, several patients relapsed (median 
PFS= 139 days). To investigate if the leukemic blasts contribute to immune 
regulatory effects, the expression of potential leukemic immune-modulators on the 
blasts, including PD-L1, INDO, PI-9, HMOX, IL-10, CXCR4 and TGF-β, was 
examined by qRT-PCR at baseline and at time of relapse. A total of 15 patients were 
screened for altered expression of these factors, either in PB (n=5) or BM (n=10) for 
both timepoints. Samples of healthy subjects (n=5), of patients with different solid 
tumor entities (n=14) and of untreated AML patients with high leukemic burden 
(n=5) served as control-groups.  
 
Figure 31: Whisker Plots showing alterations in the expression of different immune modulators 
in samples of vaccinated AML-patients at two distinct time points compared to control groups. 
Vaccinated AML patients were compared to healthy controls, untreated AML-patients and to a 
compound of different solid tumors (Table 14) for elevated expression of CD274, TGF- β, HMOX 
CXCR4, IL-10, PI-9 and INDO (A through G). The dotted line represents the mean value of the 
healthy control group. Interestingly, only the immune modulator CD274/PD-L1 is significantly altered 
when comparing expression in week 10 to that at baseline (A). No further significant alteration, at 
least between the two vaccine time points, can be observed (B-G). * = p ≤ 0.05; ** = p ≤ 0.01; *** = p 
≤ 0.001; ns = not significant. 
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For all immune modulators a significant higher expression in relation to the house-
keeping gene PBGD was observed in healthy subjects when compared to the 
untreated AML patients (range: p= *** to p= 0.058, Figure 31 A through G). 
Significant differences in expression between untreated and vaccinated patients prior 
to vaccination were only detected for of PD-L1 and INDO (p= * and p= 0.057, 
respectively; Figure 31 A and C).  
 
 
Figure 32: Whisker Plots showing alterations in the expression of different immune modulators 
in samples of vaccinated AML-patients at two distinct time points and PFS-subsets (LP, SP) 
compared to control groups. Vaccinated AML patients were compared to healthy controls, 
unvaccinated AML-patients and to a compound of different tumor entities for elevated expression of 
CD274, TGF- β, HMOX CXCR4, IL-10, PI-9 and INDO (A through G). The dotted line represents 
the median value of the healthy control group. A) CD274 expression varies significantly in a group of 
patients that exhibits a longer PFS (LPFS, > 139 days, p= *). Interestingly no oppositely regulated 
process appears in the SPFS subgroup. B) Differential expression of TGF- β eypression can be 
observed between both subgroups. (C-G) As in the previous figure, no further significant alteration, at 
least between the two vaccine time-points, can be observed.  * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 
0.001; ns = not significant. 
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Concerning the intra-regimental relation, only PD-L1/CD274 (Figure 31 A) showed 
a significantly altered expression (p= *) at baseline (median = 0.0067; mean = 0.013) 
and at the time point of relapse (median = 0.0027; mean = 0.012). 
This is of special interest, since in section 4.2.1 we describe a significant correlation 
of the PD-L1-receptor PD-1 with progression-free survival. 
As additional analyses we subsequently divided the 15 patients into two subsets, long 
(LPFS) and short progression-free survival (SPFS), according to the median PFS (>139 
days, n=9; ≤139 days, n= 6; respectively) and revaluated.  
As a result, a significant decrease in PD-L1/CD274 expression during vaccination 
could be correlated to a higher PFS (p= *; Figure 32 A). Prior to vaccination the long 
performing subset of patients exhibited an increased level of PD-L1 (median = 0.016; 
mean = 0.017) in relation to the healthy control subset (median = 0.006; mean = 
0.005). At the time-point of relapse, the long performing subset exhibited values of 
PD-L1 expression close to that of healthy controls (median = 0.003; mean = 0.005). 
In contrast, the SPFS subset showed no alterations. Even though the means of both 
time-point differ (baseline = 0.005; relapse = 0.021), median values stayed similar to 
that of the healthy control subset (baseline = 0.005; relapse = 0.006).  
A second interesting aspect is the opposite regulation of TGF-β expression in the 
short- and long PFS subsets (Figure 32 B). While the SPFS subset exhibited a decrease 
in TGF- β during vaccine administration (baseline: mean = 0.025; median = 0.017; 
relapse: mean = 0.01; median = 0.005; p = 0.067), the LPFS subset presented an 
increase in TGF- β expression (baseline: mean = 0.02; median = 0.0044; relapse: 
mean = 0.03; median = 0.02; p = 0.059). 
4.5 Summary of individual immune modulative mechanisms in 
the patient collective 
Our data suggests that, at least in our setting, vaccine efficacy is not influenzed by a 
single specific immune modulatory mechanism, since we can not observe any 
significant correlation of the selected immune modulators to clinical outcome. 
Nevertheless, while theses modulators do not exert a general effect, their presence 
and induction in individual cases surely may influence the individual outcome of the 
single patient. For this reason we summarized the individual parameters to gain 
insight in the distribution of these parameters among our patients (Table 18). 
 
Results 
 81 
 WT1-Panel Immunmodulatory  
 FACS PCR FACS  
Patient ΔCCR7 PD-1 ΔTreg ΔMDSC ΔCXCR4 ΔTGF-β ΔIL-10 ΔINDO ΔCD274 ΔHMOX ΔPI-9 ΔMDSC PFS 
1 1.09 Low (0.06%) 0.64 0.09 0.97 1.61 0.41 0.23 0.17 0.38 0.48 0.68 514 
2 0.99 Low(0.2%) 1.29 2.29 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 978 
3 n.a High (1.15%) 2.69 2.44 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 136 
5 n.d. n.d. n.d. n.d. 1.46 3.22 39.5 11.54 19.90 10.14 2.64 17.28 37 
6 0.81 High (5.06%) 1.55 0.27 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 201 
7 1.45 Low (0.42%) 1.75 0.16 0.04 0.11 6.22 16.78 0.49 0.11 2.47 4.68 128 
8 n.a. i.h. (2.09%) 1.15 5.70 n.a. n.a. 1.26 0.13 n.a. 3.58 0.40 8.44 49 
9 n.d. n.d. n.d. n.d. 23.90 16.71 0.12 0.02 0.03 2.37 0.55 0.12 310 
10 0.81 n.d. n.d. n.d. 1.01 0.84 0.70 0.53 1.06 0.26 1.10 41.77 262 
11 0.78 High (3.83%) 2.05 0.94 1.89 1.98 5.32 1.43 1.92 2.03 1.65 0.29 101 
12 0.67 High (1%) 0.75 2.29 0.94 3.99 0.11 0.30 0.23 1.41 0.04 0.49 144 
15 0.80 Induced (3x) 2.12 4.22 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 57 
17 n.d. n.d. n.d. n.d. 35.57 3.99 28.18 4.11 2.91 8.67 0.97 4.99 339 
18 0.84 Low (0.19%) 3.09 0.11 0.06 0.56 0.04 0.02 0.06 0.07 0.16 0.46 142 
19 0.42 Induced (3x) 0.93 16.47 0.01 0.43 2.28 0.05 0.08 0.02 0.04 2.40 69 
20 0.80 Induced (11x) 0.39 0.28 9.36 6.44 12.37 10.14 12.71 1.85 14.30 19.54 132 
21 0.51 Low (0.14%) 0.20 0.48 5.82 6.45 3.08 13.83 4.09 1.72 4.08 0.30 149 
  22* 1.17 Low (0.2%) 1.00 4.27 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 1682 
24 1.12 n.d. n.d. n.d. 0.30 1.65 0.60 0.80 0.12 2.84 0.14 2.81 504 
25 1.07 High (0.92%) 1.83 0.27 0.47 12.02 0.005 0.48 0.53 0.62 3.32 0.01 147 
 26† 1.36 Low (0.61%) 0.90 0.35 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 99 
Mean   1.39 2.54 4.69 3.18 5.06 3.83 2.05 1.69 2.30 6.95 294.29 
Median   1.22 0.71 0.97 1.81 1.02 0.67 0.49 1.56 0.96 2.40 144.00 
Table 18: Summary of the presence of immune modulatory effects in the individual patients. 
Blue highlights indicate potential negative effects on vaccine efficacy. Missing values in the WT1-
panel derive from limited material stocks. Blanks in the immunodulatory panel are attributed to the 
differential clinical outcome, as not all patients went into relapse, therofore not beeing available for 
blast analyses. * the patient is still in SD. † the patient relapsed but could not be analysed due to 
sample limitations. 
 
The different blast-associated immune modulatory mechanisms are 
hetereogenously distributed among the patients and the presence of elevated 
levels of the same can be observed in 13 out of 15 patients at time point of 
relapse. Additionally, 15 out of 17 patients exhibit elevated T reg or MDSC levels 
as well as restrained CTL-functionality. 
We appointed to each of these effects a score value and plotted the total, 
accumulated amount of each patient versus the clinical outcome in terms of PFS. 
As seen in Figure 33, the accumulation of multiple immune modulatory 
parameters can asymptotically be related to a shorter progression-free-survival. 
Patients with the accumulation of multiple „detrimental“ factors therefor exhibit a 
shorter PFS than patients with only few immune interfering factors as outlined in 
Table 19.  
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Figure 33: Correlation of the multiplicity of aquired immune modulative mechanisms and PFS.  
Patient 26 was excluded in this graph, as the missing analysis of blast-associated immune evasive 
mechanisms could not be performed. ° the patient is still in SD. 
 
Unfortunately, the low number of patients included in our study does not allow to 
proove this statistically. Nevertheless, this trend should be taken into account when 
optimizing future treatments. 
Total N PFS-Range [days] PFS-mean [days] Table 19: Accumulation 
of immune modulatory 
mechanisms in patients 
and association to PFS. 
The accumulation of 
immune evasive 
mechanisms leads to a net 
reduction of progression 
free-survival. 
0 1 514 514 
1 1 1682 1682 
2 3 142 - 978 766 
3 4 136 - 201 287.75 
4 2 57 – 147 102 
5 4 49 – 144 97.5 
7 1 339 339 
8 2 37 – 149 93 
9 1 101 101 
10 1 132 132 
4.6 Generation and expansion of WT1-specific T cells 
As noted, the recognition of altered cells by the immune system is a crucial step in 
tumor eradication. The low-affinity-level between TCR and TAA may produce a 
TAA-specific antigen-threshold below which T cells are not fully activated. In the 
context of WT1128-134, detailed analyses focusing on the lytic capacity of WT1128-134-
specific T cells towards leukemic blasts are missing. 
This is mainly attributed to the fact, that, up to date, no stable expansion of WT1-
specific T cells could be established. Despite the presence and induction of WT1128-
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134-specific T cells in peripheral blood and bone marrow of vaccinated patients, it 
reamains very difficult to expand WT1-specific T cells in vivo. As it appears that 
succesfull expansion of WT1-specific T cells depnds upon cell culture conditions 
[266], several protocols were tested for optimization of T cell expansion (Table 20) 
during this work.  
 
Protocol Cytokines Details Processing Outcome 
1 IL-2 / IL-7 Cells are primed with 
peptide and IL-2 (50 
IU/ml) / IL-7 
(2400IU(=10 ng/ml) 
Expansion for 10 days, every 2nd day 
addition of IL-2, every 7th day IL-7 
Effective growth, numerous 
colonies. Low tetramer-
frequencies (up to 2 %). Poor 
cytokine response. No killing. 
2  IL-2 / IL-4 
/ IL-7 
Cells are primed with 
peptide and IL-4 (5 
ng/ml) / IL-7 (5 ng/ml)  
Expansion for 10 days, every 2nd day 
addition of IL-2 and IL-4 
No functional difference to the 
SOP. Slightly increased killing 
if compared to SOP. 
3  IL-2 Cell-sorting and 
incubation with feeder 
cells and 120 U IL-2. 
Every 2nd day addition of IL-2. Numerous colonies, but no 
specificity, no killing. 
(probably due to mal-sorting) 
4  IL-7 / IL-
12 / IL-2 
Cells are primed with 
peptide. 
On day 1 addition of IL-7 (20 ng/ml) 
and IL-12 (0.5 ng/ml). Then every 
2nd day addition of IL-2 (30IU/ml). 
Weekly restimulation with irradiated 
and primed PBMCs.  
Poor cell growth, isolated 
colonies. Low tetramer-
frequencies (up to 1, 2 %). 
Mainly TNF-α-producers. No 
killing 
5 IL-7 / IL-
10 / IL-12 / 
IL-2 
Cells are primed with 
peptide. 
On day 1 addition of IL-7 (20 ng/ml), 
IL-10 (10 ng/ml) and IL-12 (0.1 
ng/ml), Then every 2nd day addition 
of IL-2 (30IU/ml). 
Weekly restimulation with irradiated 
and primed PBMCs.  
Effective growth, numerous 
colonies. Low tetramer-
frequencies (0, 87 %). Mainly 
TNF-α-producers. No killing 
6 IL-6 / IL-
12 / IL-2 
Cells are primed with 
peptide. 
On day 1 addition of IL-6 (10 ng/ml) 
and IL-12 (5 ng/ml). Then every 2nd 
day addition of IL-2 (30 IU/ml). 
Weekly restimulation with irradiated 
and primed PBMCs. 
Effective growth, numerous 
colonies. High tetramer-
frequencies (8, 37 %). Mainly 
TNF-α-producers. No killing 
7 IL-7 / IL-
15 / IL-2 
Cells are primed with 
peptide. 
On day 1 addition of IL-7 (20 ng/ml), 
on day 5 addition of IL-15 (5 ng/ml). 
Then every 2nd day addition of IL-2 
(30IU/ml). 
Weekly restimulation with irradiated 
and primed PBMCs. 
Poor cell growth, isolated 
colonies. Low tetramer-
frequencies (max 0, 6%). 
Mainly TNF-α-producers. No 
killing 
8 IL-6 / IL-
12 / IL-2 / 
IL-7 
Cells are primed with 
peptide. 
On day 1 addition of IL-6 (10 ng/ml) 
and IL-12 (5 ng/ml). Then every 2nd 
day addition of IL-2 (30 IU/ml) and 
every 7th day IL-7 (10 ng/ml).Weekly 
restimulation with irradiated and 
primed PBMCs 
Effective growth, numerous 
colonies. High tetramer-
frequencies (constant rates of 
5%). 
Mainly TNF-α-producers. 
Table 20: Listing of the applied expansion protocols during this work 
 
In cooperation with the group of Per Thor Straten in Herlev, Denmark PBMCs of 
two patients (P22 and P12) with high WT1128-134-Tetramer frequencies were thawed 
and prepared for a live experiment on FACSDiva, i.e. stained with fluorochrome-
conjugated antibodies to CD3 (FITC), CD8 (PE) and with fluorochrome-conjugated 
WT1128-134-Tetramers (APC) (Protocol 3.). 
Small lymphocytes were gated by FSC and SSC and further discriminated by CD3, 
CD8 and WT1128-134-Tetramer gating. CD8 / WT1128-134-Tetramer double positives 
were sorted as single cells into 96 well plates, containing approx. 105 feeder-cells per 
well together with phytohemagglutinin (PHA) and 120 U/ml IL-2. Plates were 
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incubated and medium was changed every 3-4 days. Following 10 – 14 days of 
incubation, growing clones were transferred into new 96 well plates together with 
feeder cells and further expanded. 
 
Figure 34: 51Chromium-
release assay to detect WT1-
specific clones upon FACS 
selction. Growing clones of 
two patients were tested in a  
51Chromium-release assay, to 
determine the selction specifity 
of the performed cell sorting. 
pink = specific lysis, purple = 
unspecific lysis. 
A total of seven outgrowing clones were selected for patient 22 and a total of three 
clones for patient 12, respectively. Unlikely no specific WT1128-134 specific 
cytotoxicity, exhibited by the selected clones could be detected by a 51Chromium-
release Assay (Figure 34).  
Cytokine Potential effect 
IL-2 Stimulates growth, differentiation and survival of CTLs 
IL-4 Enhances T cell proliferation 
IL-6 Induces a transcriptional inflammatory response (JAK-STAT/MAP-Kinase) 
IL-7 Promotes T cell survival and development 
IL-10 Stimulates T cells 
IL-12 Enhances cytotoxic activity of CTLs 
IL-15 Stimulates cell proliferation and activation 
Table 21: Activities of the cytokines included in the different expansion protocols. 
This was in concert with the analogously performed WT1128-134-Tetramer staining, 
which also proofed poor specificity of the corresponding clones. As direct selection 
of WT1128-134-Tetramer-positive T cells from PBMCs seemed to be inadequate for 
efficient and stable expansion of these cells, the experimental setting was altered to 
an initial stimulation of PBMCs with WT1128-134 and consecutive incubation with 
different expansion cocktails (protocols 4 - 8).  
In cooperation with Dr. Agnieszka Wieczorek and Prof. Dr. Lutz Uharek, different 
expansion protocols, based on different cytokine-cocktails were tested (Table 20).  
Experiments performed with samples from three different patients revealed that 
protocol 4, based on IL-6 and IL-12 initially resulted in sufficient amounts of WT1-
specific T cells. The consecutive modification of the post-stimulation processing by 
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adding IL-7 (protocol 8) resulted in a stable selection of WT1-specific T cells, 
oscillating at a frequency of 5% and seems to be the most efficient protocol.  
 
Figure 35: WT1-specificity of expanded T cells in BM and PB. T cells were expanded using 
WT1126-134-peptide together with IL-6 and IL-12 for initial boosting, as well as IL-2 and IL-7 for 
consecutive maintenance. A) Bone marrow-derived lymphocytes exhibit WT1-specific frequencies of 
3% in the total CD3+ fraction and 20% in the CD3+CD8+ fraction, respectively. B) PBMC-derived 
lymphocytes exhibit WT1-specific frequencies of 28% in the total CD3+ fraction and 41% in the 
CD3+CD8+ fraction, respectively. A control staining of the PBMC sample with an HIV-Tetramer 
excluded unspecific staining of the corresponding WT1-tetramers (data not shown). 
We further modified the protocol, and by combination with the MACS-technique, we 
succeeded in expanding WT1-specific T cells in frequencies up to 40% of PB-
derived CD3+CD8+ T cells (Figure 35).To further characterize these expanded WT1-
specific T cells, a RT PCR-based relative Vβ-family quantification approach [267], 
established in an associated lab, was performed. 
After separation of WT1-Tetramer+-T cells from their negative counterparts by 
MACS, both subsets were screened for Vβ -chain family expression. The subsets 
differ significantly in their Vβ -chain family phenotype (Figure 36). The WT1-
Tetramer- fraction, composed of unprimed irradiated PBMCs, exhibits a variation of 
different Vβ –chains, with focus on Vβ 2, Vβ 6a and Vβ 8. In contrast, the isolated 
WT1-Tetramer+-T cell fraction is mainly composed out of cells expressing Vβ 7 (up 
to 90 %). 
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Figure 36: Distribution of TCR- Vβ -chain families in the differential subsets of expanded T 
cells.  A) WT1-Tetneg cells do exhibit a broad and heterogeneous range of different TCR- Vβ –chain 
families. B) In contrast, the MACS-sorted WT1-Tetpos cells mainly express the TCR- Vβ –chain 
family HBV7 (~90%) suggesting monoclonality of the selected WT1-specific T cells. 
4.7 Tumor recognition and eradication  
In preparation for experiments testing the ability of WT1-specific T cells to 
recognize and eradicate autologous and allogeneic leukeimic cells suitable assays 
were established during this work.  
As a proof of principle, we screened several leukemic cell lines for their suitability as 
target cells for the detection of WT1-specific cytokine production and cytotoxicity, 
respectively. We also screened the available leukemic cell lines on their expression 
profiles on HLA-A2 and WT1. Out of 6 leukemic cell lines 4 turned out to be HLA-
A2 positive (Figure 37 A). The HLA-A2 negative cell line Molt-4 was subsequently 
used as a negative control in all peptide loading experiments. 
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Figure 37: Expression profiles of available leukemic cell lines. A) Surface staining of different 
tumor cell lines with anti-HLA-A2. Except for HL-60 and Molt-4, all remaining cell lines present 
HLA-A2 on their surface. B) Intranuclear staining of the same tumor cell lines with anti-WT1. All cell 
lines express the transcription factor WT1. Interestingly, in the case if UT-7, only a small proportion 
of cells seems to be WT1+. 
In the case of WT1-expression, 5 cell lines were significantly positive for the 
transcription factor, whereas the cell line UT-7 exhibited only a negligible amount of 
WT1-positivity (Figure 37 B).  
In a next step, we incubated four HLA-A2 positive cell lines (K562-A2, THP-1, TF-
1 and UT-7) as well as one HLA-A2 negative cell line (Molt-4) with an HLA-A2-
restricted Influenza A-peptide or an irrelevant HIV-peptide. When cultured over-
night together with HLA-A2+ T cells, expanded for 14 d after priming with the same 
Influenza A-peptide, specific secretion of IFN-γ and TNF-α could determined by 
flow-cytometry. No specific cytokine production of Influenza A-specific T cells 
could be observed when incubated together with the HLA-A2 negative cell line Molt 
4 (Figure 38 A). In contrast, all four HLA-A2 positive cell lines were able to 
specifically activate the expanded T cells (Figure 38 B).  
In addition to the analyses of WT1-dependent cytokine production we were looking 
for suitable assay to directly determine WT1-specific cytotoxity. The first attempts 
were designed according to publications by Schmid et al. [268], Lecoeur et al.[269] and 
Fischer et al.[270] , using fluorescent dyes for live/dead discrimination. In brief, target 
and effector cells were stained with an exclusion marker (CFDA-SE or PKH-26), the 
target cells were loaded with the antigenic peptide and coincubation was performed 
for 24 h. Cytotoxicity was the determined by amount of AnnexinV+-cells in the 
target population.  
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Figure 38: Characterization of leukemic cell lines in order to specifically activate antigen-
primed T cells. Influenza A- primed PBMCs from an HLA-A2+Influenza+-donor were co-incubated 
with different leukemic cell lines, loaded with HLA-A2-restricted Infuenza A (FLU)- or an irrelevant 
peptide (HIV) and screened for cytokine release. A) The HLA-A2 negative cell line Molt-4 is not able 
to specifically activate Influenza A-primed T cells. B) In contrast, all 4 HLA-A2 positive cell lines 
activate Influenza A-primed T cells as can be observed by the enhanced cytokine release in the 
Influenza A-loaded setting. C) Column bar graph, indicating the specific activation of primed PBMCs 
in the different leukemic cell lines in regards to the stimulation with both peptides. In contrast to the 
negative control Molt-4, all other cell lines specifically activate Influenza-primed PBMCs as observed 
by an at least 2-fold increase of cytokine release in response to FLU-loaded cells in comparison to 
HIV-loaded cells.    
 
These assays perform quite effective when dealing with sufficient cell numbers and 
T cell specifities. As we had to notice that the expansion of WT1-specific T cells 
usually leads to low frequencies of usable effector-cells, we started to screen for a 
more sensitive assay. In cooperation with the group of Dr. A.M. Kaufmann we 
established a cytotox-assay for our needs[244].  
The VITAL-FR assay, which has been published in 2004 by Hermans et al. [271], 
combines specific and unspecific killing in one experiment. Target cells are 
differentially labeled with fluorescent dyes and loaded with a) the target peptide or b) 
a control peptide. As the differentially loaded cells can be attributed to specific 
colors, lysis can be determined flow cytometrically by the ratio of the remaining 
viable control and target cells (Figure 39 B). 
Results 
 89 
Target cells are splitted, differentially labeled and loaded with peptides
CFSEFarRed
AntigenControl-Peptid
cells are mixed and co-incubated with specific effector cells
R1
R2
CFSE
F
ar
R
ed
100%
1
2
1
2













Con
pos
R
R
R
R
Lyse
A B
C
F
ar
R
ed
F
ar
R
ed
 
Figure 39: Methodical setting of the VITAL-FR assay to determine specific cytotoxicity. A) 
Preparations for the VITAL-FR assay. The target cell line is splitted and differentially labeled with 
fluorescent dyes. After labeling, the two subpopulations are either loaded with the specific antigen or 
a control peptide.  B) Schematic experimental illustration: With increasing amount of effector cells 
(grey), the amount of antigen-loaded cells is decreasing, thus affecting the ratio between the two 
cellular subsets. C) Equation leading to the net percentage of lysed cells.  
 
Under optimal conditions the VITAL-FR assay is supposed to be able to significantly 
detect cytotoxic effects induced by three specific CTL[244]. In a first attempts to 
determine if this assay is suitable in our leukemic context we performed an 
experiment in which differentially labeled UT-7 cells were loaded with either an 
HLA-A2-restricted Influenza A- or HIV-peptide. These cells were consecutively co-
cultured with Influenza A-primed T cells at different E.T ratios overnight and 
analysed flow-cytometrically (Figure 40 A).  
 
Figure 40: Preliminary testing of the VITAL-FR assay in a leukimc context. A) Flow-cytometric 
analysis of an experiment with leukocytic material of donor 1. After initial exclusion of the 
lymphocyte population, the tumor cells are displayed according to their initial labeling with FarRed or 
CFSE, implicating the loading with Influenza A- or HIV-peptide. B) The comparison of the different 
fluorochrome ratios in the context of increasing E:T rations leads to lytic saturation curve for both 
experimental approaches. 
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The experiment was performed in duplicate, using two different Influenaza-reactive 
donors. The corresponding graph (Figure 40 B) clearly shows the posititive lytic 
capacity of both T cell populations, thereby proofing the suitability of the VITAL-FR 
assay in a leukemic context. 
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5 Discussion 
This work describes the monitoring of humoral and cellular immune responses in 
patients with AML in the context of a peptide-based anti-cancer vaccine and the 
potential complex immune-restrictions caused by functionally impaired tumor-
specific T cells or immune evading leukemic blast interfering with vaccine efficacy.  
Prior to vaccination all patients had active AML or were at high risk of early relapse 
after chemotherapy. In brief, the vaccination with WT1 peptide together with KLH 
and GM-CSF as adjuvants [93] demonstrated unexpected clinical efficacy by 
stabilization of the disease in a substantial number of patients with active AML and 
delayed relapses in half of the high-risk patients. The clinical responses was 
correlated to the molecular efficacy with 52% of patients, in which WT1-mRNA 
levels in PB decreased to at least one third compared to baseline. The number of 
patients with induced WT1128-134-specific T-cells increased from 28% at baseline to 
76% in week 10 demonstrating immunological efficacy, which was however not 
correlated to molecular or clinical efficacy of WT1-peptide vaccination. Despite 
these encouraging results most of the patients relapse after a certain time, which 
made an additional detailed immunomonitoring and the analyses of potential immune 
escape mechanism necessary.  
5.1 Evaluation of humoral reactivity to the vaccination with WT-
1-peptide plus GM-CSF and KLH 
In the context of tumor eradication, as well as in many other pathological conditions, 
the humoral part of the immune system plays an important role, as demonstrated by 
several clinical therapies using directed antibodies to mark tumor cells and facilitate 
tumor recognition [31, 272] and destruction. 
In the case of the tumor antigen WT1, several studies have described the presence of 
spontaneous natural humoral immune responses against WT1 in patients with WT1-
expressing hematopoietic malignancies in vitro and in vivo [124]. Based on this data, 
we analyzed the WT1 specific humoral response induced by the administration of an 
HLA-A201 restricted epitope of WT1 (WT1126–134) in combination with KLH and 
GM-CSF. Additionally, we evaluated if the induction of WT1-antibodies can also 
serve as serological marker for vaccine efficacy by analyzing whether the induction 
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of WT1-specific IgM-antibodies was associated with the clinical outcome and 
survival of the patients. 
 
In our specific vaccine setting, we were able to demonstrate an induction of WT1-
specific IgM-antibodies but not antibodies with an IgG-subtype in response to 
consecutive treatment. As the majority of initial IgM-responses was detected around 
week 26/30 (5 out of 7 patients) we started to investigate if the lack of isotype-switch 
was due to time reasons or a lack of specific B cell/T-helper cell interaction. This is 
of special concern, as in our specific setting the immunogenic part of vaccine is 
composed of a MHC-class I-restricted epitope, intentionally designed to activate 
CD8+ T cells. In contrast to the induction of M-isotype immunoglobulins, the 
secretion of G-isotype immunoglobulins requires the transformation of a B cell into a 
plasma cell, a process which is initiated upon CD40 stimulation through CD4+ T-
helper cell interaction. Indeed, further experiments revealed that in our study we 
were unable to induce WT1- specific CD4+ cells. One can further speculate that the 
lysis of leukemic blasts by vaccine-induced CTLs seems to be insufficient to provide 
further “natural” WT1 epitopes for alternative T-helper cell stimulation. 
 
Concerning the suitability of WT1 antibodies as serological marker, we could 
observe a significant number of patients with a favourable clinical course (SD or 
remission) who also had elevated titers of WT1-specific IgM antibodies, compared to 
those who did not respond clinically to the WT1 vaccination therapy (PD or relapse).  
 
Our data is in line with most other HLA-Class-I-epitope-based vaccines, which 
generally show poor ability to induce balanced activation of CD4+ - and CD8+ -T cell 
subsets, which might be essential for effective, long-lasting antitumor immunity. 
Indeed, a current publication describes HLA-A2-restricted responses that efficiently 
kill tumor cells but are characterized by a limited lifespan in the absence of CD4+ 
helper T cells [231]. 
 
Data from Nicoli et al. suggest that natural induction and isotype-switching of WT1-
specific immunoglobulins depends on strong and persistent stimulation with WT1 as 
only seen in patients with high-blast count [273], but not in healthy subjects. As WT1 
seems already to be a naturally weak B-cell stimulus, which is in line with the 
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reported absence of toxicity and autoimmune phenomena after WT1 vaccination [133], 
the administration of only an HLA-A201-restricted epitope seems to be detrimental 
to the conversion of WT1-specific IgM to IgG.  
 
These conclusions are supported by the fact that the administration of the “non-self”-
protein KLH as immunostimulant resulted in the induction of both, IgM- and IgG-
antibodies, specific for KLH, proofing an otherwise intact conversion system. In 
contrast to WT1, KLH was administered as an intact protein and could be processed 
in APCs to deliver both, MHC-class I and MHC-class II restricted epitopes. It is 
known, that protein-based vaccines are capable of generating stronger CD4+ 
responses, but – unfortunately - at the cost of less effective induction of CTLs [274].  
 
The induction of anti-KLH immunoglobulins precedes the one of anti-WT1 
immunoglobulins as observed in different vaccine settings using KLH [92] and is 
presumably a result of a boost of naturally occurring anti-KLH antibody 
responses[275]. These data are consistent with the preliminary testing of negative 
controls. Two healthy donors showed an elevated spontaneous response to KLH, 
probably due to oral tolerance and were consequentially excluded as controls. 
 
A long-term vaccination with an HLA-A2/MHC class I- restricted peptide is 
therefore able to induce WT1-specific IgM antibodies. But the failure to induce IgG 
antibodies gives evidence that specific T-helper-cell induction by the MHC class I 
peptide, KLH and GM-CSF is lacking for induction of isotype switch of B cells, 
leading to optimal immune response against WT1. Nevertheless, these results 
demonstrate that anti-WT1-IgM can be used as serological marker for treatment 
efficacy.  
Most of the remarks described above could be bypassed by the use of longer peptides 
eligible for intracellular processing, or the combination of several different epitopes 
in the same vaccine. One possibility to enhance the efficacy of vaccines would be the 
use of WT1-Pepmixes, comprising the entire WT1 protein, split into overlapping 
peptides of 15 AA and therefore combining both features, in eliciting long lasting 
and complete immune responses.  
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5.2 Evaluation of T cell functionality and anergy 
In our previous work, we could demonstrate immunogenicity of our specific vaccine 
setting, as observed by the induction of TAA-specific T cell responses in 52% of the 
patients during time-course. Nevertheless, these responses were predominantly short 
term effector responses and could be transformed into long-lasting memory 
responses in only a few cases, In addition this work was intended to reveal pontential 
cellular effects detrimental to vaccine efficacy. The efficacy of cancer 
immunotherapy strongly relies in addition to external factors, e.g. the selection of an 
appropriate epitope as well as a suitable delivery system, on the individual 
immunological status of the treated patient. On this account, therapy-related 
monitoring of T cell functionality as well as periodically screening for potential 
mechanisms interfering with proper T cell function should represent a necessity in 
cancer immunotherapy. As the latter field still resides in an investigative state, 
context-specific markers for appropriate or failing T cell functionality have to be 
identified during early phase-studies. 
 
While immediate protection is conferred by circulating or tissue-resident effector 
memory T cells, recall responses are mediated by central memory T cells that patrol 
the T cell areas of secondary lymphoid organs where they can rapidly proliferate and 
respond with greater vigor upon re-encounter with the same pathogen [202, 276]. The 
migration to the SLOs requires the expression of so-called homing-receptors, of 
which CCR7 is attributed to central memory T cells [199].  
 
The results presented in this work show, that a vaccine-induced increase in CCR7-
frequencies in CD8+ T cells is associated with a better prognosis in terms of 
progression-free survival. The opposite is true for patients with decreased 
frequencies compared to baseline. These patients exhibit a significantly shorter 
progression-free survival than patients with increased CCR7 values (p< 0.01). As 
both groups did not inherit significant differences in CCR7 expression at baseline, 
one can speculate if the variances in CCR7 frequencies are provoked by individual 
circumstances leading to a beneficial response or if they are the result of a general 
mechanism modulating the differentiation and the proliferative potential of T cells 
and/or T cell exhaustion or anergy.  
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Interestingly, an addendum presented at the 2011 ASCO meeting (abstract 2503), 
referring to a recently published study on the effect of Ipilimumab-treatment in 
resected melanoma patients [277] by Sarnaik and collegues, equally demonstrated an 
association of decreased CCR7-frequencies with relapse and/or death in their patient 
cohort. As Ipilimumab is designed to interfere with the immune checkpoint factor 
CTLA-4, a molecule triggering T-cell anergy, the consecutive eradication of residual 
disease and hence the clinical outcome are mainly affected by the effector-capacity 
of the patients’ T cells. Thus individuals with sufficient amounts of Tnaïve and Tcm-
cells, i.e. CRR7-expressing phenotypes should exhibit a beneficial clinical 
performance. In accordance with this assumption, Sarnaik et al. additionally 
observed a parasllel increase of eomesdormin-frequencies in T-cells of patients with 
relapse or death, wich represents an additional indicator for a late maturation status 
and therefore reduced lifespan of the corresponding T-cells [278]. 
 
It is hypothesized, that long-term maintenance of an immunological memory would 
be dependent on cells that retain their proliferative capacity [279], which is a 
characteristics of TCM rather than TEM cells 
[280]. Consecutive encounter with an 
antigen may result in immunological tolerance towards the antigen in terms of 
impaired activation or induced anergy of antigen-specific T cells. As in any other 
immunogenic context, only a small fraction of the tumor-specific cells present at the 
peak of the immune response survives as memory cells in the peripheral lymphoid 
organs[281]. Further confrontation with the specific antigen induces recall responses 
mediated by central memory T cells, which can rapidly proliferate and differentiate 
into effector memory T cells, displaying immediate effector functions. However, 
recent studies have shown that repeated boosting, as performed in our vaccination 
scheme, can drive memory T cells toward terminal differentiation[282, 283] 
accompanied by reduced or no proliferative and reconstitution capacity of TEM, as 
well includes the risk of depleting the population of central memory T cells.  
 
On this account, the monitoring of a specific patient in our collective is quite 
interesting: the patient achieved a complete remission for 12 month and the expanded 
WT1-specific T cell clones were analysed by qRT PCR quantification for all TCR 
Vβ-families. A specific predominant clone was identified during clinical remission 
and was present in PB and BM after 8 vaccinations. During further vaccination 
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course the transcript levels in BM decreased and at relapse frequencies of the specific 
clone raised only in PB but not in BM [284]. These data, support the present findings 
on impaired memory function as well provide first data regarding evolution and 
compartmentalization of a peptide vaccine-induced T cell clone in PB and BM. 
 
As a part of this work was intended to investigate potential effects of T-cell 
exhaustion we were able to demonstrate that, in fact, vaccine efficacy also is strongly 
determined by the actual exhaustion status of the lymphocyte population at therapy 
initiation. 
The results show that increased PD-1 values at baseline could be associated to a 
shorter PFS (median =132 days; p=0.05) in contrast to patients with initially low PD-
1 frequencies. In addition, these subsets not only differed in terms of PFS but also in 
terms of a molecular response towards the vaccine. Low PD-1 values at baseline 
were clearly associated (p=0.057) with a functional molecular response, as observed 
by a net reduction of WT1-mRNA levels in week 10.  
Notably, the major knowledge about the PD-1/PD-L1 pathway derives from murine 
tumor models [160, 285, 286]. On this account and despite the xenogeneic differences, our 
data is in concordance with two systemic models of murine AML established in the 
USA [16, 287]. Both models proofed increased resistance to AML in PD-1(-/-) knockout 
mice in contrast to wild-type-mice and additionally proofed increased function of 
CTLs at tumor sites upon PD-1/PD-L1 blockade. These effects support the 
assumption that increased PD-1 frequencies at an early stage of immunotherapy may 
be crucial for long-term PFS. 
 
Taken together, the data on T-cell functionality suggest that consecutive vaccination 
may lead to reduced proliferative capacity of T cells, interfering with a proper 
induction of an immunologic memory. Further, our data suggests, elevated PD-1 
expression, prior to vaccination or acquired, is crucial for long-term relapse-free 
survival. In contrast, constantly low or reduction of PD-1 seems to account for 
favorable prognosis, an effect close to observations in chronic viral infections [288].). 
The same outcome holds true in regards of the PD-1 ligand PD-L1 on leukemic 
blasts: AML patients in which blasts increase PD-L1 expression, tend to relapse 
earlier, than do the low-PD-L1 counterparts. 
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5.3 Impact of escape mechanisms of leukemic blasts on vaccine 
efficacy 
In addition to an inert immunologic tolerance or poor response towards the tumor, 
tumor progression may also be facilitated by the induction of suppressive effects or 
escape phenomena by the tumor itself (c.f. section 1.4). The hematopoietic 
descendance of leukemias leads to an exclusive situation, as the two opponing forces, 
the leukemic blasts as well as the targeting immune cells, potentially revert to a 
similar transkriptome[14] and/or signalome[13]. On this account the deciphering of 
potential immunomodulatory effects of the leukemic blasts towards the immune 
response represents a clinically importance as well as scientifically interesting aspect 
of immune monitoring in AML and other leukemias. 
 
Along with stimulatory modulators like TGF-β and CXCR4, that act ubiquitously on 
most cell-types and therefore are frequently found in a broad range of different 
neoplasias, this work also focused on the role of negative factors that naturally 
appear in an immunologic context. In fact, investigations on PI-9, IDO, IL-10, 
HMOX and PDL1, that play a regulative role in immune privilege, peripheral 
tolerance and/or other immunomodulatory pathways, comprised the largest 
component regarding this section of the presented work. 
 
In our specific setting, these blast-associated modulators were hetereogenously 
distributed among the patients but could not significantly be associated to a general 
therapeutic effect. Nevertheless, their presence and induction in individual cases 
surely may influence the individual outcome of single patients.  
 
In coincidence with the gathered PD-1 data, PD-L1/CD274 showed a significantly 
altered expression during vaccination which could be correlated to a higher PFS (p= 
*; Figure 32 A) in affected patients. Despite a diversified range of individual PD-L1 
expression levels among different patients and tumor entities when compared to 
healthy controls, the median values of PD-L1-mRNA levels seem to be on a similar 
level with those of healthy controls. However, in our specific setting, a fraction of 
our patients exhibited an elevated median level of PD-L1 mRNA at baseline which 
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significantly declined during therapy. Interestingly, these exclusively were patients 
who benefitted the most from the vaccination and had longer PFS.  
 
The explanations are speculative, but it may be possible, that a conjuncture of the 
differentiation status of the tumor progenitor cell as well as the de novo induction of 
“non-exhausted“ WT1-specific T cells may lead to such an effect. Indeed, it has been 
recently described that PD-L1 expression differs on hematopoietic progenitor cells, 
according to the maturation status and the environmental inflammatory conditions 
[289] in patients after HSCT. Additionally, in a murine model of AML, Zhang et al 
observed that PD-L1-expression is elevated on murine C1498 blasts growing in an in 
vivo context when compared to the same cells cultured in vitro [16], but that external 
administration of IFN-y to the in vitro culture leads to a leveling of both expression 
patterns. 
These data points to the general importance of the PD-1/PD-L1 pathway in immune 
evasion by a hematologic malignancy, but also provides additional information on 
individual parameters enhancing this effect. Nevertheless, these data equally supports 
the necessity of current and future clinical trials targeting this pathway in leukemia 
patients. 
 
When comparing our patients to healthy controls and unvaccinated AML-patients we 
also observe that AML-patients in general seem to have lower TGF-β values than 
have healthy controls. This effect may be a molecular response to reduced TGF-β 
signaling in AML caused by functional change of SMAD4, as described earlier [290].  
When retaining the previous discrimination in patients with short and long PFS, 
TGF-β-mRNA levels perform oppositely: While TGF-β ratios are reduced in the 
short-PFS subset, TGF-β values increase in the patients with longer PFS (Figure 32 
B). In theory, when the patients relapse, it is assumed that TGF-β might act as a 
tumor-promoter. It appears paradox that a reduced TGF-β-expression should lead to 
an increased tumor progression, while augmented TGF-β-expression delays tumor 
spreading. But this effect might be explained by the bifurcated downstream events in 
case of loss of TGF-β signaling[17]: 
As mentioned earlier, transforming-growth-factor-β plays an important role in tumor 
initiation and progression, functioning as both a suppressor and a promoter. TGF- β 
normally supports homeostasis and suppresses tumor progression. However, a break 
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in its pathway triggers tumor growth and metastasis. Mutations of the genes encoding 
TβRI and TβRII, or decreased expression and phosphorylation of other components 
of this pathway, have been reported in human cancers [17]. 
TGF-β suppresses tumor initiation and early development through the inhibition of 
cell cycle progression, induction of apoptosis, and suppression of growth factor, 
cytokine and chemokine expression. Relying on the kind of TGF-β–signaling 
disruption, tumor initiation and promotion occur differentially. Impairment in the 
early phase of the TGF-β signal cascade, e.g. loss or mutation of signaling 
components, such as TGF-β-receptors, results in rapid growth, i.e. increased mitosis 
rates and therefore increased probability of further cancer-driving mutations, and 
rapid tumor progression. In contrast, perturbations in the downstream process lead to 
an either slow expanding tumor but make it more invasive and more likely to 
metastasize [17]. As we observed different timeframes for tumor relapses, further 
analyzes should focus on identifying the specific casualties responsible for the TGF-
β variances. 
5.4 Evaluation of immune regulatory cells 
Functional impairment of tumor-specific T cells not always is a result of classical 
exhaustion and/or modulation by tumor cells: There also exist naturally occurring 
regulatory cells, intended to avoid collateral damage caused by over-reactive or 
obsolete cellular immune reactions. These cells, in this work we only concentrate on 
MDSCs and Tregs, represent an additional crucial feature for vaccine efficay that 
either may be induced naturally or may be provoked by the tumor to serve as 
interference to anti-tumor immunity. 
MDSC are one of the major factors responsible for immune suppression in cancer. 
They also contribute to limited efficacy of current vaccination strategies. As seen in 
different clinical settings, the amount of MDSC is elevated in our AML patients 
compared to healthy controls. Despite the detection of an MDSC-decrease during 
vaccination, the latter effect could not be proven to be statistically significant 
associated with favorable clinical course. Nevertheless, the increased frequencies of 
MDSC point to a potentially restricted immune response in individual patients.  
 
An interesting aspect concerning this subject is the consecutive administration of 
GM-CSF as part of our vaccination regimen. Physiologic concentrations of GM-CSF 
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are required for normal myelopoeisis and DC differentiation. However, excessive 
amounts of this growth factor could exert immune suppressive effects and could be 
responsible for induction of MDSC as shown by twot studies, in which the 
administration of GM-CSF resulted in significantly increased numbers of MDSCs 
[291, 292]. Filipazzi et al.analyzed MDSC modulation by a HSPPC-96/GM-CSF 
vaccine in stage IV melanoma patients. When compared to stage-matched melanoma 
patients who received HSPPC-96 alone, CD14+HLA-DR-/lo MDSC-frequencies and 
TGF-β plasma levels were augmented after administration of the GM-CSF-based 
vaccine [293]. This led to the assumption that GM-CSF-based vaccinations per se may 
be able to potentially expand immune suppressive MDSCs.  
In fact, a second study by Solito et al. showed that promyelocyte-like BM-MDSCs 
can be generated from human BM-cells after treatment with a combination of G-CSF 
and GM-CSF [292]. Additionally, these cells excerted immunosuppressive functions in 
presence of lymphocytes and were considered equivalent to MDSC in the blood of 
breast and colorectal cancer patients.  
 
Similar results were obtained consideringr the Treg compartment. Regulatory T cells 
mediate amelioration of disease and immune homeostasis by inhibiting immune 
activation and maintaining peripheral immune tolerance. The suppressive 
mechanisms and clinical significance of Treg have not been completely uncovered in 
patients with acute myeloid leukemia, but several reports have shown that increased 
frequencies of circulating CD4+CD25high Treg in patients with AML provide 
suppressive activity compared with those from healthy controls [294-296].  
In our patients, at baseline, we were able to detect elevated levels of CD4+CD25high 
CD127low when compared to healthy controls. When the Treg-frequencies at baseline 
were aligned with those in week 10, we pictured a quite heterogeneous development. 
We could monitor increase as well as reduction of Treg-frequencies in different 
patients, as well as stable Treg-frequencies in a few patients. Unfortunately these 
effects could not be correlated to clinical outcome or PFS. Similar effects have been 
previously described in the context of immunotherapy [297], probably due to a 
secondary response to therapy-induced inflammation as equally observed in 
chemotherapeutic settings [296].  
It has been shown, that tumor-derived MDSC induce tolerance by expanding 
naturally occurring tumor-specific Treg 
[231, 265, 298], but mainly in murine systems. 
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There exist only few data concerning this effect in human settings, but data is 
controversial. However, we could not find any indication in our patient population 
that MDSC and Treg cells might be linked in a common immunoregulatory network 
that involves both myeloid and T cells, as proposed by others. The monitoring of our 
vaccine trial showed that the percentage of Treg cells was invariably high throughout 
tumor growth but did not relate to the kinetics of accumulation of the MDSC 
population. This reliance could also be observed by Ko et al. [299] and Movahedi et 
al. [300], with the latter suggesting that MDSCs are not necessarily required for Treg 
induction and maturation. Conclusive evidence supporting or rejecting such 
interaction in humans needs to be satisfactorily confirmed in further studies. 
5.5 Expansion of WT1-specific T cells  
The stable detection, enumeration and in vitro-expansion of antigen-specific T cells 
are of major importance in T cell immunology and its application in targeted therapy. 
A detailed characterization of antigen-specific T cells leads to multiple potential 
applications in cancer therapy, e.g. treatment with in vitro expanded TAA-specific T 
cells and/or the generation of TCR-gene-modified T lymphocytes for adoptive T cell 
therapy, respectively. 
On this account and depending on the application, minimum quantities of TAA-
specific T cells have to be sampled, expanded and preserved for further processing.  
In the context of WT1, strategies to expand specific CTLs have been proofed to be 
labourous and rarely result in satisfactory amounts of WT1-specific T cells. 
Investigations on in vitro methods to expand WT1-specific T cells in patients and 
healthy individuals mainly include DC-stimulation [266] as well as WT1-
peptide/pepmix-stimulation [301-303], usually generating frequencies ranging from 1 to 
6 % of total CD3+CD8+ cells.  
 
The establishment of WT1 specific T cells in our institution was preceded by the 
evaluation and comparison of several protocols. In one patient we were able to 
expand WT1-specific T cells to frequencies of 21% of D3+CD8+WT1-tetramer+ T 
cells from a PB-sample and 48% 21% of D3+CD8+WT1-tetramer+ T cells generated 
from a BM-sample, respectively. To our knowledge, this is the first time that such 
high frequencies could be reported after expansion of natural WT1-specific T cells 
by WT1-peptide stimulation.  
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However, these results represent an exceptional and time consuming work effort by 
means of repeated restimulation of the expanded T cells with irradiated, epitope-
loaded APCs and repeated purification by the MACS technique. Up to date, we were 
not able to successfully transfer this approach to samples collected from other 
patients in our trial. Notably, among our patient population, patient 22 uniquely 
exhibited constantly elevated levels of WT1-tetramer specific T cells including stable 
frequencies of WT1-tetramer specific-TEM-cells (c.f. Figure 26). As TEM- cells 
exhibit an increased proliferative capacity, these cells might be preferable as basis 
for the expansion of WT1-tetramer specific T cells. In fact, viral-specific 
approaches have been shown to be more effective when expanding ex vivo memory 
T cells [304, 305]. 
 
Contradictotily, some publications concerning the expansion of WT1-specific CTLs 
also describe the induction of WT1-specific T cells out of material derived from 
normal healthy donors [266, 301, 303, 306] as detected by multimer staining. For example, 
Weber et al. demonstrated that HLA-A1- and HLA-A2-restricted WT1-specific 
CTLs could be generated in a limiting dilution assay from the CD8+ lymphocyte 
fraction of 4 out of 10 healthy adult donors [303]. These cells exhibited similar 
functional and lytic tumor reactivity like those equally generated from samples of 
breast cancer patients (4 out of 9). Ho et al. also reported succesfull generation of 
WT1-specifc T-cells (up to 18% after the 3rd stimulation) out of PBMCs of healthy 
donors by using a DC-based approach [266]. Surprisingly, the group around M. Stamer 
even described the serendipitous expansion of WT1-specific CTLs from CMVpp65-
stimulated CD8+ cells [307]. Taken together, these data would suggest that WT1 
specific T cells represent an easy-to-generate subset of the naïve T cell repertoire, 
contradicting the experienced difficulties in the ex vivo expansion of patient-derived 
natural WT1-specific CTLs and in establishing a permanent population of WT1-
specific T lymphocytes in hematological cancers [93, 100, 135]. 
 
Despite first initiatives to harmonize guidelines for HLA-multimer assays[248], the use 
of non-standardized and non-validated assays is still common. This fact exludes 
direct comparison of gathered data by different labs [308] and hence makes data 
potentially questionable. This complex situation and the personal experience on the 
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pitfalls on the evaluation of multimer-staining data support the need for unbiased and 
harmonized evaluation criteria. 
 
It was recently shown by our group, that a predominant TCR  chain of the Vβ-21-
family was associated with vaccine induced complete remission in an AML patient 
(patient 1) in our setting [284]. In a follow-up study, the question was adressed 
whether this predominant clone could be found in other AML patients vaccinated 
with WT1 peptide (paper in review). In this context, TCR- Vβ analyses of CTLs from 
patient 22 prooved to include T cells expressing a similar Vβ-21 TCR phenotype as 
the one predominantly expressed in patient 1.  
Having access to a high frequency of ex vivo expanded WT1-specific T cells of 
patient 22, we investigated if these cells also exhibit a unique phenotype concerning 
their TCR- family. The obtained data concerning the Vβ –chain-families indicated 
that, in contrast to the in vivo population, up to 90 % of the ex vivo expanded WT1-
specific T cells predominantly expressed the Vβ-7-chain. Taken together this data 
support the assumption, that a single epitope peptide vaccination may result in inter-
individual sharing of TCR structures [284], but also indicates that predominancy of a 
specific clone may be the result of individual and rather independent circumstances.  
5.6 Summary and outlook 
To briefly summarize our results, the generated data demonstrates that in our specific 
setting, in which AML patients received consecutive vaccinations with HLA-A201-
restricted WT1126–134 epitope together with GM-CSF and KLH, impaired vaccine 
efficacy is mainly attributed to restricted T cell functionality. As summarized in 
Figure 41, immune resistance mechanism exerted by leukemic blasts do not 
generally influence clinical outcome in our setting. Neither do inert 
immunoregulative mechanisms like Treg or MDSC, respectively.  
There is evidence that these mechanisms may have effects in individual cases, but 
general correlation with vaccine efficacy could not be demonstrated according to our 
results. In contrast, restrained vaccine efficacy seems to be a result of impaired 
effector phase of the immune system, as seen by an initial high level of anergic 
markers in patient which exhibit a quite short PFS. The failure to induce a long-term 
memory is mirrored by the decrease of T cells expressing the homing-receptor CCR7 
as well as by the observation that WT1-specific T cells may not be able to migrate to 
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the site of tumor at relapse. Our results indicate that the vaccine-induced increase in 
CCR7+CD8+ memory T cells may represent a surrogate marker for clinical efficacy 
in vaccination and warrants evaluation in future clinical trials. Based on these data, 
future tasks concerning vaccination therapies should try to ameliorate the induction 
and maintenance of tumor-specific T cells. Further, the appropriate migration of 
these cells to the lymph nodes and SLOs, as well as to the actual tumor site should be 
provided by the vaccine regimen.  
 
 
Figure 41: Mechanisms of immune resistance during vaccination: correlation with unfavorable 
clinical course, progression-free survival or relapse. * Data generated by Busse et al. [128]; # Data 
generated by Ochsenreither et al. [284] 
 
Additionally, our data suggest that the PD-1/PD-L1 pathway plays an important role 
in limiting the host immune response in AML patients vaccinated with WT1 peptide, 
KLH and GM-CSF. On this account, and as recently proposed by others [16, 289], the 
evaluation of protective blocking antibodies against PD-L1 or PD-1 in patients with 
leukemia should be strongly considered (cf. Figure 11, section 1.5.2). This issue 
would be of special concern in vaccination therapy, as consecutive vaccination leads 
to chronic activation of anti-tumor T cells, one major cause for PD-1 induction. 
 
A special point, in relation to peptide-based vaccinations is the predominant 
administration of single epitopes to elicit a tumor-specific immune response. As seen 
in our trial, the application of a specific epitope restricted to MHC-class I molecules 
does not sufficiently activate the entire immune repertoire. The administration of the 
adjuvant KLH indeed mimics the co-stimulation of CD4+ T cells by an otherwise 
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presented epitope via MHC-class II, but it seems that for an effective tumor response 
the identical provenance of both stimuli is beneficial. For this reason, future 
vaccination designs should either shift to the administration of combined MHC-class 
I and MHC-class II restricted epitopes of tumor antigens or to overlapping peptides. 
The latter peptides faciliate the uptake and processing by APCs and should result in a 
stable presentation of epitopes on both classes of MHC molecules circumventing the 
competitive kinetics of actual epitope based therapies. 
 
An alternative and interesting approach, represent BiTE-(bispecific T cell-engager)-
antibodies. These antibodies are constituted of two oppositely directed variable 
regions of conventional immunoglobulins that are connected by a linker to form a 
single polypeptide chain and have been designed to transiently connect any T cell 
with cancer cells for initiation of redirected target cell lysis [309, 310]. All BiTE 
antibodies share the anti-CD3 specific single-chain antibody linked to an individual 
target-antigen-specific single-chain antibody, which allows T cell activation and 
potentially directs any CTL to deal with tumor cells.  
 
However, despite the recent promising results in the field, cancer immunotherapy 
still offers a lot to learn about the underlying immunological mechansisms of cancer 
vaccination and its improval. This work and that of others show that cancer 
vaccination remains a prosperous, attractive and very important field of research that 
actually has to deal with four main tasks: a) the adaption of a ranking process of 
exisiting and novel tumor antigens, b) the alignment of criteria for the immunological 
evaluation of cancer vaccine trials, c) the improvement of biological adjuvants to 
trigger specific immune responses and d) the investigation and application of 
bystander-therapies reducing immune evasive and/or immune modulative effects. 
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